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Autosomal dominant hyper-IgE syndrome (AD-HIES) is typically caused by dominant-negative (DN) STAT3mutations. Patients
suffer from cold staphylococcal lesions and mucocutaneous candidiasis, severe allergy, and skeletal abnormalities. We report 12
patients from 8 unrelated kindreds with AD-HIES due to DN IL6ST mutations. We identified seven different truncating
mutations, one of which was recurrent. The mutant alleles encode GP130 receptors bearing the transmembrane domain but
lacking both the recycling motif and all four STAT3-recruiting tyrosine residues. Upon overexpression, the mutant proteins
accumulate at the cell surface and are loss of function and DN for cellular responses to IL-6, IL-11, LIF, and OSM. Moreover,
the patients’ heterozygous leukocytes and fibroblasts respond poorly to IL-6 and IL-11. Consistently, patients with STAT3 and
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IL6ST mutations display infectious and allergic manifestations of IL-6R deficiency, and some of the skeletal abnormalities of IL-
11R deficiency. DN STAT3 and IL6ST mutations thus appear to underlie clinical phenocopies through impairment of the IL-6
and IL-11 response pathways.
Introduction
Job’s syndrome was first described in 1966 in patients with re-
current “cold” staphylococcal abscesses, eczema, and respiratory
infections (Davis et al., 1966). In 1972, high serum IgE levels were
found in patients with this condition, which was then renamed
hyper-IgE syndrome (HIES; Buckley et al., 1972; Zhang et al.,
2018b; Bergerson and Freeman, 2019; Buckley, 2020). These
patients also often have eosinophilia, low levels of inflammatory
markers during infection, chronic mucocutaneous candidiasis
(CMC), and extrahematopoietic disorders, including skeletal
lesions in particular (e.g., deciduous tooth retention, osteopenia,
and scoliosis; Grimbacher et al., 1999a; Chandesris et al., 2012a).
HIES is typically inherited as an autosomal dominant (AD) trait
(Grimbacher et al., 1999a). Disease-causing monoallelic DN
missense variations of the gene encoding signal transducer and
activator of transcription 3 (STAT3) were first reported in 2007
in patients with the full HIES phenotype (Minegishi et al., 2007).
Over 100 different rare variants of STAT3 have since been re-
ported (Holland et al., 2007; Renner et al., 2007; Chandesris
et al., 2012b; Vogel et al., 2015; Khourieh et al., 2019). In some
kindreds, typical HIES segregates as an autosomal recessive (AR)
trait (AR-HIES). Some patients with AR-HIES carry biallelic null
mutations of the zinc-finger 341 gene (ZNF341), encoding a
transcription factor governing basal and inducible STAT3 ex-
pression (Béziat et al., 2018; Frey-Jakobs et al., 2018). AR DOCK8
and PGM3 deficiencies and AD CARD11 deficiency are not ge-
netic etiologies of bona fide HIES, as affected patients have high
serum IgE levels and eczema in the context of clinical manifes-
tations not seen in ZNF341 and STAT3 deficiencies and lack
many clinical phenotypes of these deficiencies, including weak
inflammation and characteristic extrahematopoietic disorders
(Zhang et al., 2009, 2014, 2018b; Engelhardt et al., 2009; Sassi
et al., 2014; Ma et al., 2017).
STAT3 is a signaling molecule acting downstream of many
cytokine receptors, such as IFNAR1, IL-6R, IL-10R, IL-11R, IL-21R,
IL-22R, IL-23R, oncostatin M (OSM)–R, and leukemia inhibitory
factor (LIF)–R; Kane et al., 2014). The multisystemic nature of
the clinical phenotypes seen in AD-HIES patients probably re-
flects this pleiotropy. Complete Stat3 deficiency is embryonic
lethal in mice (Takeda et al., 1997). However, AD-HIES patients
retain residual STAT3 activity, and mice with DN germline
mutations of Stat3 and a similar degree of residual STAT3 ac-
tivity are born healthy (Steward-Tharp et al., 2014). These mice
have high levels of IgE expression and are susceptible to bacte-
rial infection but do not fully reproduce the HIES phenotype,
making it difficult to decipher the pathogenesis of individual
human HIES phenotypes. By contrast, the progressive identifi-
cation of human inborn errors of cytokines or of their receptors
signaling through STAT3 have clarified several HIES pheno-
types. Some related deficiencies do not have phenotypes over-
lapping with HIES. Patients with IL-23R deficiency suffer
from isolated mycobacteriosis (Martı́nez-Barricarte et al.,
2018), patients with IL-10RA or IL-10RB deficiency suffer from
inflammatory bowel disease (Glocker et al., 2011; Kotlarz et al.,
2012; Moran et al., 2013), and patients with IFNAR1 or IFNAR2
deficiency suffer from severe viral infections (Duncan et al.,
2015; Hernandez et al., 2019). Other deficiencies overlap with
HIES. Patients with IL-21 or IL-21R deficiency share some of the
features of HIES, with high serum IgE concentrations, recur-
rent respiratory infections, and impaired humoral immune
responses. However, unlike HIES patients, they also display
severe cryptosporidiosis (Kotlarz et al., 2013, 2014; Salzer et al.,
2014; Erman et al., 2015; Stepensky et al., 2015). Patients with
IL-11RA deficiency suffer from craniosynostosis and den-
tal abnormalities, without significant immunodeficiency
(Nieminen et al., 2011). Patients with LIF-R deficiency develop
Stüve-Wiedemann syndrome (SWS), a multisystem disorder
characterized by profound bone defects and disordered respi-
ratory, cardiac, and autonomic nervous systems (Dagoneau
et al., 2004). These patients also develop scoliosis, osteoporo-
sis, and dental abnormalities. Few patients with SWS survive
the neonatal period. Patients with partial OSM-R deficiency
develop pruritus and cutaneous amyloidosis (Arita et al., 2008).
Patients with complete IL-6R deficiency develop recurrent skin
and lung infections, eczema, high IgE levels, abnormal acute-
phase responses, and eosinophilia (Spencer et al., 2019; Puel
and Casanova, 2019).
IL6ST encodes GP130, a signaling receptor subunit used by all
IL-6 family cytokines, including IL-6, IL-11, IL-27, LIF, OSM, IL-
35, cardiotrophin-1, cardiotrophin-like cytokine, and ciliary
neurotrophic factor (Rose-John, 2018). In mice, complete GP130
deficiency is lethal in utero due to myocardial, hematological,
and skeletal defects, reflecting the pleiotropic role of this mol-
ecule (Yoshida et al., 1996; Kawasaki et al., 1997). A condition
similar to SWS, with skeletal malformations, respiratory failure,
and perinatal death, was recently reported in fetuses and pa-
tients homozygous for loss-of-function (LOF) mutations in IL6ST
(Monies et al., 2019; Chen et al., 2020). By contrast, patients with
AR partial, as opposed to complete, GP130 deficiency present
recurrent lung infections, eczema, eosinophilia, high serum IgE
levels, impaired acute-phase responses, craniosynostosis, scoli-
osis, and deciduous tooth retention (Schwerd et al., 2017; Shahin
et al., 2019). The proximal cytoplasmic region of GP130 contains
two boxes that constitutively bind JAKs (Lütticken et al., 1994).
Upon cytokine activation, JAKs phosphorylate tyrosine residues
767, 814, 905, and 915 in the cytoplasmic domain of GP130,
leading to the recruitment and activation of STAT1, STAT3, and,
to a lesser extent, STAT5 (Lütticken et al., 1994; Hunter and
Jones, 2015; Murakami et al., 2019). No known cytokine can
activate GP130 in the absence of another receptor chain. IL-6 and
IL-11 first bind IL-6R and IL-11R, respectively, forming a hexa-
meric complex with GP130 with a valence of 2:2:2 (Murakami
et al., 1993; Barton et al., 2000). IL-27, LIF, and OSMuse IL-27RA,
LIF-R, and OSM-R, respectively, to form a heterotrimer with
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GP130 (Gearing et al., 1992; Mosley et al., 1996; Pflanz et al.,
2004). IL-6R and IL-11R cannot signal through their own intra-
cellular domains. Consequently, these cytokines rely on GP130
for their function. By contrast, IL-27RA, LIF-R, and OSM-R can
recruit STATs via specific motifs present in their intracellular
domains.
In this context, the less severe outcome of patients with AR
partial GP130 deficiency than of those with AR complete GP130
deficiency can be explained by the apparently largely intact LIF
signaling and impaired, but not abolished, IL-6, IL-11, IL-27, and
OSM signaling (Schwerd et al., 2017; Shahin et al., 2019; Monies
et al., 2019; Chen et al., 2020). No deficiencies of IL-27RA or
ciliary neurotrophic factor receptor have been described, but
most of the immunological and extrahematopoietic phenotypes
of patients with AR partial or complete GP130 deficiency have
been seen in patients lacking IL-6R, IL-11R, LIF-R, or OSM-R
deficiency (Schwerd et al., 2017; Shahin et al., 2019; Spencer
et al., 2019; Nieminen et al., 2011; Mikelonis et al., 2014; Arita
et al., 2008). Collectively, these findings suggest that many,
perhaps even most, of the immunological abnormalities seen in
patients with STAT3 deficiency, whether biological (high IgE
levels), clinical (atopy and recurrent staphylococcal infections),
or both (low levels of inflammation), are due to poor cellular
responses to IL-6 (Puel and Casanova, 2019), whereasmost of the
skeletal abnormalities are due to poor responses to IL-11 (cra-
niosynostosis and deciduous tooth retention) or LIF (scoliosis,
osteoporosis). The apparent lack of CMC in patients with AR
deficiency of IL-6R, IL-10RA, IL-10RB, IL-11R, IL-21R, IL-23R,
IFNAR1, IFNAR2, LIF-R, or OSM-R deficiency (Schwerd et al.,
2017; Spencer et al., 2019; Nieminen et al., 2011; Mikelonis et al.,
2014; Arita et al., 2008; Mart́ınez-Barricarte et al., 2018;
Hernandez et al., 2019; Glocker et al., 2011; Kotlarz et al., 2014;
Duncan et al., 2015) also suggested that the pathogenesis of
impaired IL-17 immunity and CMC in patients with mutations in
STAT3 or ZNF341 may involve the disruption of multiple cyto-
kine responsive pathways (Minegishi et al., 2007; Puel et al.,
2011; Béziat et al., 2018; Ma et al., 2016). We tested whether
new genetic etiologies of AD-HIES could shed light on the
pathogenesis of various individual HIES phenotypes.
Results
Rare monoallelic IL6ST variants in HIES patients
We investigated 12 patients with HIES from 8 unrelated families
of French (kindreds A and B), Bulgarian (kindred C), Slovakian
(kindred D), American (kindreds E, G, and H), or Turkish
(kindred F) origin (Fig. 1, A and B; and Table S1). With the ex-
ception of the parents of P6 (kindred C), who were second
cousins, none of the patients were known to be the fruit of
consanguineous unions. This presence or absence of consan-
guinity was confirmed by the high or low percentage of homo-
zygosity on whole-exome sequencing (WES) in five patients (P2,
P3, and P4 = 0.17%, P5 = 0.28%, and P6 = 2.0%). In kindreds A and
C, the HIES phenotype was observed in several consecutive
generations of affected male and female individuals, consistent
with segregation as an AD trait. The other patients (P5 and
P8–P12) had no family history of HIES. Mutations of STAT3were
excluded in the first two kindreds identified by targeted se-
quencing of all exons and sequencing the full-length cDNA of P2
(kindred A) and P5 (kindred B). We performed WES for 10 pa-
tients. No candidate mutations were found in known HIES-
causing and other primary immunodeficiency genes, including
ZNF341, IL6R, DOCK8, TYK2, PGM3, and STAT3. By contrast, all 10
patients carried a heterozygous stop codon or frameshift mu-
tation in IL6ST (Fig. 1, A and C). P2, P3, and P4 (kindred A)
carried a heterozygous duplication of 5 nt (c.2277_2281dup) re-
sulting in a frameshift followed by a premature stop codon 29
amino acids downstream (p.T761Ifs*29, subsequently abbre-
viated to T761fs; Fig. 1, A and C). P5 (kindred B) and P6 (kin-
dred C) carried the same heterozygous duplication of
one adenine residue (c.2155dup), resulting in a frameshift
and a premature stop codon two amino acids downstream
(p.I719Nfs*2, subsequently abbreviated to I719fs; Fig. 1, A and C).
P8 (kindred D) carried a heterozygous substitution of 1 nt
(c.2199C>A), resulting in a premature stop codon (p.C733*; Fig. 1, A
and C). P9 (kindred E) carried a heterozygous deletion of one
thymidine residue (c.2121del), resulting in a frameshift followed
immediately by a premature stop codon (p.L708*; Fig. 1, A and C).
P10 (kindred F) carried a heterozygous substitution of one
nucleotide (c.2277T>G), resulting in a premature stop codon
(p.Y759*; Fig. 1, A and C). P11 (kindred G) carried a hetero-
zygous duplication of one thymidine residue (c.2224dup),
resulting in a frameshift and a premature stop codon two
amino acids downstream (p.S742Ffs*2, subsequently abbre-
viated to S742fs; Fig. 1, A and C). P12 (kindred H) carried a
heterozygous substitution of 1 nt (c.2261C>A), resulting in a
premature stop codon (p.S754*; Fig. 1, A and C). Sanger se-
quencing confirmed the mutations in all eight kindreds, and
confirmed that P7 was heterozygous for the p.I719fs. The fa-
milial segregation patterns of the mutant alleles were con-
sistent with an AD trait with full penetrance (Fig. 1 A). The
mutations in P5 (c.2155dup), P9 (c.2121del), P10 (c.2277T>G),
and P11 (c.2224dup) had occurred de novo. The c.2155dup,
which occurred in two unrelated families, is therefore re-
current not because of a founder effect but probably due to a
mutational hotspot. None of the seven mutations was re-
ported in any public database (Bravo, gnomAD v2.1, and
ClinVar). All mutations were predicted to be highly delete-
rious, with combined annotation-dependent depletion scores
of 29.7, 27.0, 40.0, 26.3, 35.0, 33.0, and 40.0, respectively,
well above the mutation significance cutoff of 3.3 (99% con-
fidence interval) for IL6ST (Itan et al., 2016). All these IL6ST
variants clustered in the intracellular C-terminal region
(Fig. 1 C). All the mutated alleles were predicted to encode
receptors that (1) reached the cell surface, as the premature
stop codon was downstream from the transmembrane do-
main; (2) accumulated at the cell surface, due to the trunca-
tion of the STQPLL recycling motif (Dittrich et al., 1996); and
(3) were LOF, due to the truncation of the four STAT3-
docking sites (Stahl et al., 1995). This triad of features
is strikingly similar to that of DN mutations of IFNGR1
(Jouanguy et al., 1999), suggesting that these IL6ST mutations
may be DN and pathogenic. Consistent with this hypothesis,
truncated forms of mouse and human GP130 retaining cell
Béziat et al. Journal of Experimental Medicine 3 of 24
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surface expression but with no STAT3 docking sites have been
shown to exert a DN effect on IL-6 signaling (Kumanogoh et al.,
1997; Selander et al., 2004).
Population genetics of human IL6ST
Intriguingly, 13 predicted LOF heterozygous mutations in IL6ST
(essential splicing site mutations, premature stop codons, and
frameshift mutations), all with combined annotation-dependent
depletion scores >20 and minor allele frequencies <10−4, have
been reported for 14 donors in the gnomAD database (Fig. 1 C;
Zhang et al., 2018a). Nine of these reported rare variants are
predicted to lack the transmembrane domain and, therefore,
to abolish cell surface expression, suggesting that hap-
loinsufficiency at the IL6ST locus is unlikely to be disease
causing in our HIES patients. By contrast, the remaining four
public LOF variants are predicted to be normally expressed at the
cell surface and retain the STQPLL recyclingmotif (Dittrich et al.,
1996).Moreover, these four variants lack only one (p.L906Hfs*28
and p.G913Rfs*10, hereafter referred to as G913fs), two (p.E899*),
or three (p.S789*) of the four STAT3-binding residues (tyrosine
767, 814, 905, and 915) of GP130 (Fig. 1 C; Stahl et al., 1995). The
p.L708*, p.I719fs, p.C733*, p.S742fs, p.S754*, p.Y759*, and p.T761fs
mutations found in the eight HIES kindreds are, therefore, the
only seven variants predicted to reach the cell surface and lack
both the recycling motif and all four STAT3-binding sites within
the IL6ST intracellular domain. The absence of all four STAT3-
binding sites suggests that all seven mutations are LOF, and the
lack of the recycling motif suggests that they accumulate at the
cell surface, thereby potentially interfering with normal GP130
signaling via a DNmechanism. By contrast, themutants reported
Figure 1. AD IL6ST deficiency. (A) Pedigree of
the eight unrelated families showing familial
segregation of the c.2277_2281dup (p.T761fs)
mutant IL6ST allele in kindred A, the c.2155dup
(p.I719fs) mutant IL6ST allele in kindreds B and C,
the c.2199C>A (p.C733*) mutant IL6ST allele in
kindred D, the c.2121del (p.L708*) mutant IL6ST
allele in kindred E, the c.2277T>G (p.Y759*)
mutant IL6ST allele in kindred F, the c.2224dup
(p.S742fs) mutant IL6ST allele in kindred G, and
the c.2261C>A (p.S754*) mutant IL6ST allele in
kindred H. M, mutant. Individuals of unknown
genotype are labeled “E?”. The father of P12, who
died at 26 yr of age, is shown in gray because he
suffered from a phenotype partially compatible
with HIES (asthma, multiple infections, rheu-
matoid arthritis, and diverticulitis). (B) Repre-
sentative photographs and scanner images of
patients, with scoliosis (P5), lung pneumatocele
(P5, P6, P9, and P10), bronchomalacia (P3, red
arrow), cold abscess (P8, black arrow), and si-
nusitis (P9, green arrow). (C) Schematic repre-
sentation of GP130 and population genetics of
IL6ST alleles. All reported predicted heterozy-
gous “LOF” alleles and their positions in GP130
are indicated. The L708*, I719fs, C733*, S742fs,
S754*, Y759*, and T761fs mutations found in the
patients under study are colored in red. Mutants
reported in gnomAD are colored in black, green,
or blue. Two variants from gnomAD with a pre-
mature stop codon before the transmembrane
domain were selected for subsequent functional
analysis and are colored in green (E316* and
T555fs). Three variants from gnomAD with a
premature stop codon lacking one (G913fs), two
(E899*), or three (S789*) STAT3-binding resi-
dues were selected for subsequent functional
analysis and are colored in blue. EC, extracellular
domain; IC, intracellular domain; SP, signal pep-
tide; TM, transmembrane domain.
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in gnomAD v2.1 are predicted to be LOF (but not DN, as they are
not expressed at the cell surface), hypomorphic, or even iso-
morphic rather than DN, because they retain at least one STAT3-
bindingmotif and are not overexpressed at the cell surface. Thus,
the population genetics of IL6ST highlights the striking features
specific to the variants seen in HIES patients.
The HIES-associated GP130 mutants accumulate at the cell
surface
Using CRISPR/Cas9, we first generated a human embryonic
kidney (HEK) 293T cell line lacking GP130 expression (referred
to hereafter as HEK-GP130-KO). We transfected HEK-GP130-KO
cells with complementary DNAs (cDNAs) encoding WT GP130,
two mutants lacking the transmembrane domain (E316* and
T555fs), or mutants retaining the transmembrane domain but
lacking one (G913fs), two (E899*), three (S789*), or four (L708*,
I719fs, C733*, S742fs, S754*, Y759*, and T761fs) STAT3-binding
residues (Fig. 1 C). SDS-PAGE of cell extracts followed by
Western blotting and immunodetection with a monoclonal anti-
GP130 antibody (clone E8, raised against amino acids 365–619)
showed that the WT protein was produced at a mol wt of ∼140
kD, which is higher than the predicted mol wt (∼103 kD; Fig. 2 A).
The T555fs (predicted mol wt ∼63 kD), L708* (predicted mol
wt ∼80 kD), I719fs (predicted mol wt ∼82 kD), C733* (predicted
mol wt ∼83 kD), S742fs (predicted mol wt ∼84 kD), S754*
(predicted mol wt ∼85 kD), Y759* (predicted mol wt ∼86 kD),
T761fs (predicted mol wt ∼89 kD), S789* (predicted mol wt ∼89
kD), E899* (predicted mol wt ∼101 kD), and G913fs (predicted
mol wt ∼104 kD) mutants encoded truncated proteins with a
mol wt above the predicted value (Fig. 2 A and Fig. S1 A).
Surprisingly, the G913fs protein had a lower mol wt than the
WT and E899* mutant proteins (Fig. 2 A). The extracellular
domain of GP130 is highly N-glycosylated (Waetzig et al., 2010).
We therefore investigated whether the observed differences
with respect to the predicted mol wt were due to glycosylation
and whether the G913fs mutation led to the production of an
abnormally glycosylated protein. We treated cell protein ex-
tracts with peptide-N-glycosidase F (PNGase F) before SDS-
PAGE and Western blotting. This resulted in the WT and all
tested mutants migrating at a mol wt close to the expected
value, confirming that the G913fs mutant was aberrantly
N-glycosylated (Fig. 2 A). As expected, the E316* mutant (pre-
dicted mol wt ∼36 kD), which lacks the E8 mAb epitope, was
not detected in either the presence or absence of PNGase F
treatment. Extracellular staining and flow cytometry detected
the WT and all the mutants except for E316* and T555fs,
demonstrating that these two mutants lacking the transmem-
brane domain were not expressed at the cell surface (Fig. 2, B
and C; and Fig. S1, B and C). The L708*, I719fs, C733*, S742fs,
S754*, Y759*, and T761fs mutants, which lack the recycling
motif, were all expressed about three to five times more
strongly than the WT allele (Fig. 2, B and C; and Fig. S1, B and
C). By contrast, the three truncated mutants retaining the re-
cycling motif were normally (S789* and E899*) or less strongly
(G913fs) expressed than the WT (Fig. 2, B and C). The low level
of G913fs expression is accounted for by the aberrant glyco-
sylation, as GP130 stability is dependent on glycosylation
(Waetzig et al., 2010). These data suggest that all the mutants
retaining the transmembrane domain are expressed at the cell
surface, with higher levels of expression for the L708*, I719fs,
C733*, S742fs, S754*, Y759*, and T761fs mutants, due to their
accumulation at the cell surface in the absence of the
recycling motif.
The HIES-associated GP130 mutants are functionally
deleterious
We then assessed STAT3 (Y705) and STAT1 (Y701) phospho-
rylation by flow cytometry in HEK-GP130-KO cells transfected
with WT or mutant IL6ST cDNAs after stimulation with a chi-
meric IL-6/IL-6Rα protein (trans-signaling), which efficiently
triggered GP130 signaling independently of other cytokine re-
ceptor subunits. Transfection with WT GP130 restored STAT3
and STAT1 phosphorylation in HEK-GP130-KO cells (Fig. 2 D). As
expected, due to the lack of cell surface expression, transfection
with E316* and T555fs failed to restore STAT1 and STAT3
phosphorylation (Fig. 2 D). Despite cell surface expression,
transfection with the L708*, I719fs, C733*, S742fs, S754*, Y759*,
and T761fs mutants, lacking all four STAT3-binding sites, com-
pletely failed to restore STAT3 phosphorylation, whereas weak
STAT1 phosphorylationwas detected (Fig. 2 D and Fig. S1, D and E).
By contrast, mutants retaining the transmembrane domain
but lacking only one (G913fs), two (E899*), or three (S789*)
STAT3-binding sites retained the ability to phosphorylate both
STAT1 and STAT3. Phosphorylation levels were, nevertheless,
very low for G913fs, possibly due to its abnormal N-glycosylation
and weaker expression (Fig. 2, A–D; Waetzig et al., 2010). By
contrast, HEK-GP130-KO cells transfected with any of the GP130
variants displayed normal STAT1 and STAT3 phosphorylation in
response to stimulation with IFN-α (Fig. 2 D and Fig. S1, D and E).
Using the same system, but with IL-6 or IL-11 stimulation, we
found that only the WT allele could restore low levels of STAT3
phosphorylation (Fig. S1 D). Transfection with GP130 mutants
from HIES patients restored low levels of STAT1 phosphoryla-
tion after IL-27 stimulation and of STAT3 phosphorylation after
stimulation with LIF or OSM (Fig. S1, D and E), possibly due to
the intrinsic signaling potential of IL-27RA, LIF-R, and OSM-R
(Nicola and Babon, 2015; Hermanns, 2015; Murakami et al.,
2019). We then used a reporter assay to assess the ability of
each mutant to activate STAT3 signaling (Fig. 2 E and Fig. S2, A
and B). We cotransfected HEK-GP130-KO cells with an empty
vector (EV), plasmids encoding the WT or mutant GP130 pro-
teins, and a plasmid containing a luciferase reporter gene under
the control of five SIS-inducible elements (SIEs). IFN-α stimu-
lation was used as a positive control and induced luciferase in all
transfection conditions tested (Fig. S2 B). WT IL6ST transfection
induced strong luciferase activity upon stimulation with each of
the GP130-dependent cytokines tested: IL-6, IL-6/IL-6Rα, IL-11,
IL-27, LIF, and OSM (Fig. 2 E and Fig. S2 A). As reported for
transfection with the EV, transfection with the E316* or T555fs
mutants led to no induction of luciferase activity upon stimu-
lation with any of the GP130-dependent cytokines, confirming
that these two mutants were completely LOF. Mutants lacking
one to three STAT3-binding sites (S789*, E899*, and G913fs)
consistently failed to respond to IL-6 and IL-11 but had normal or
Béziat et al. Journal of Experimental Medicine 5 of 24
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Figure 2. The I719fs and T761fs IL6STmutants accumulate at the cell surface and are LOF. (A) GP130-deficient HEK293T cells were transfected with an
empty pCMV6 plasmid (EV) or with pCMV6 plasmids encoding the WT or the E316*, T555fs, I719fs, T761fs, S789*, E899*, or G913fs GP130 mutants. Total
protein was extracted, left untreated (top), or treated (bottom) for 1 h with PNGase F to eliminate N-glycosylation, and subjected to immunoblotting with a
mAb against GP130 (amino acids 365–619, clone E8). GAPDHwas used as a loading control. Western blots representative of three independent experiments are
shown. (B and C) GP130-deficient HEK293T cells were transfected as described in A. After 48 h of incubation, cells were harvested, stained for extracellular
Béziat et al. Journal of Experimental Medicine 6 of 24
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only partially impaired responses to IL-6/IL-6Rα, IL-27, LIF, and
OSM. By contrast, mutants lacking all four STAT3-binding sites
(L708*, I719fs, C733*, S742fs, S754*, Y759*, and T761fs) were LOF
for all cytokines tested, except for IL-27, for which the response
was weak (approximately one third of WT levels), but not
abolished. This partial response to IL-27 could be explained by
intrinsic signaling capacity of the intracellular domain of IL-
27RA (Pflanz et al., 2004). The T761fs mutant from P2 to P4 was
the only variant retaining the tyrosine in position 759 of GP130
(Y759) previously shown to recruit SHP2 and activate theMAPK
pathway (Stahl et al., 1995; Symes et al., 1997; Schaper et al.,
1998; Kim et al., 1998). An erythropoietin receptor–GP130 fusion
protein (extracellular domain of erythropoietin receptor fused
to the intracellular domain of GP130) including a GP130 intra-
cellular tail lacking all four STAT3-binding sites but retaining
Y759 has been reported to activate the MAPK pathway in re-
sponse to Epo despite impaired STAT3 activation (Lehmann
et al., 2003). We therefore assessed ERK1/2 phosphorylation
in the MAPK pathway by flow cytometry in HEK-GP130-KO
cells transfected with WT or selected mutant IL6ST cDNAs, after
stimulation with a chimeric IL-6/IL-6Rα protein (Fig. S2 C). We
confirmed that the WT allele induced the phosphorylation of
ERK1/2 and that the T761fs mutant retained a weak but con-
sistent ability to induce ERK1/2 phosphorylation, whereas the
other two mutants tested, I719fs and S754*, did not. Overall,
these data suggest that when overexpressed in isolation, the
L708*, I719fs, C733*, S742fs, S754*, Y759*, and T761fs mutants
are the only mutants retaining surface expression that are
completely LOF for STAT3 activation for all GP130-dependent
cytokines tested, with the exception of IL-27, for which the re-
sponse was weak, but not abolished. T761fs was the only mutant
tested that retained the ability to activate the MAPK pathway
due to its retention of the SHP2-recruiting motif.
The HIES-associated GP130 mutants are DN
As suggested by the population genetics analysis, there seems to
be no haploinsufficiency at the human IL6ST locus (Fig. 1 C). We
therefore tested the hypothesis that the L708*, I719fs, C733*,
S742fs, S754*, Y759*, and T761fs mutants exert a DN effect on the
WT allele. Using the luciferase system described above, we as-
sessed the impact of increasing the concentrations of the plasmids
encoding various mutant alleles of IL6ST cDNA while keeping the
concentration of the plasmid encoding the WT IL6ST cDNA con-
stant (Fig. 3 and Fig. S3, A–G). IFN-α stimulation was used as a
positive control and induced luciferase in all transfection con-
ditions tested (Fig. 3 and Fig. S3 G). Mutants lacking the
transmembrane domain (E316* and T555fs) or only one STAT3-
binding site (G913fs) had no DN effect on WT GP130 at any mu-
tant:WT (Mut:WT) concentration ratio, following stimulationwith
any of the six cytokines (IL-6, IL-11, IL-6/IL-6Rα, IL-27, LIF, and
OSM; Fig. S3, A–F). As expected, mutants lacking all four STAT3-
binding sites (L708*, I719fs, C733*, S742fs, S754*, Y759*, and
T761fs) exerted a potent DN effect for all cytokines tested (Fig. 3
and Fig. S3, A–F). This DN effect was very strong at low Mut:WT
ratios (0.5:1 and 1:1) for IL-6 and IL-11 signaling but was effective at
higher Mut:WT ratios (4:1 and 8:1) for the other cytokines tested
(IL-6/IL-6Rα, IL-27, LIF, and OSM). The DN effect on IL-27 and IL-
6/IL-6Rα signaling was incomplete, even at the highest Mut:WT
ratio tested. Mutants lacking two (E899*) or three (S789*) STAT3-
binding sites were not DN following IL-6/IL-6Rα stimulation for
any of the Mut:WT ratios tested (Fig. S3 B). They had little impact
on IL-27, LIF, and OSM signaling, even at high Mut:WT ratios.
However, they exerted a potent DN effect on IL-6 and IL-11 sig-
naling, although this effect was weaker than that observed with
the I719fs and T761fsmutants (Fig. S3, A and C). Given the stronger
DN effect of theHIES-causingmutants on IL-6 signaling than IL-6/
IL-6Rα trans-signaling, which does not require membrane-
anchored IL-6Rα expression on target cells, we hypothesized
that a limited pool of IL-6R might accentuate the DN effect of the
mutants on IL-6 signaling. We tested this hypothesis with the
luciferase system described above by cotransfecting HEK-GP130-
KO cells with IL6RWTcDNA togetherwithWTGP130 alone, I719fs
GP130 alone, or WT plus I719fs GP130 (ratio 1:1) before IL-6
stimulation (Fig. 4). IL-6/IL-6Rα stimulation (trans-signaling) was
performed in parallel for comparison. At a 1:1 Mut:WT ratio, as
shown in our previous experiment (Fig. 3), the I719fs mutant
exerted a potent DN effect on IL-6 signaling, but not on IL-6/IL-
6Rα trans-signaling. By contrast, in the same experimental con-
ditions, cotransfection with IL-6R abolished the DN effect of the
I719fs mutant (Fig. 4). Overall, these data show that L708*, I719fs,
C733*, S742fs, S754*, Y759*, and T761fs mutants, the only mutants
identified that accumulate at the cell surface, exert a strong DN
effect for all GP130-dependent cytokines tested, including IL-6
trans-signaling (IL-6/IL-6Rα). The DN effect on “classic” IL-6
signaling exerted by the various IL6STmutants was due, at least in
part, to the hijacking of the limited pool of transmembrane IL-6R,
accounting for the smaller impact on IL-6 trans-signaling.
GP130 production and function in primary fibroblasts
from patients
Given the skeletal abnormalities observed in the DN GP130 pa-
tients, we used flow cytometry to assess GP130 in primary
GP130 expression, and analyzed by flow cytometry. An image showing representative staining (B) and a recapitulative graph depicting GP130 mean fluo-
rescence intensity (MFI; C) are shown. The bars and error bars represent the mean of three different experiments and the standard deviation, respectively.
(D) GP130-deficient HEK293T cells were transfected as described in A. After 24 h of incubation, the cells were stimulated for 15 min with IL-6/IL-6Rα or IFN-α,
or left unstimulated, and the phosphorylation of STAT1 (pY701) and of STAT3 (pY705) was then evaluated. Representative results from three independent
experiments are shown. (E) Luciferase assay to assess STAT3 activity. GP130-deficient HEK293T cells were transfected with an empty pCMV6 vector (EV) or a
plasmid encoding theWT or the indicated GP130 mutants, plus a pGL4.47 reporter plasmid carrying the luciferase cDNA downstream from five SIEs. After 24 h,
cells were stimulated with the indicated cytokine (+) or were left unstimulated (−) for another 24 h before the measurement of luciferase activity. The
horizontal dotted line indicates the luciferase activity after stimulation, with the indicated cytokine, of the cells transfected with the empty pCMV6 vector. The
results shown are the mean and standard error of the mean for a technical duplicate. Luciferase assays representative of three independent experiments
are shown.
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fibroblasts from patients and healthy controls (Fig. 5, A and B).
We found that the fluorescence intensity of GP130 in P2 (T761fs)
and P5 (I719fs) was approximately seven times higher than that
in healthy controls. Western blotting suggested that these higher
levels of surface GP130 expression on flow cytometry were due
to the accumulation of the mutant proteins at the cell surface
(Fig. 5 C). Indeed, we detected normal levels of the WT protein
and abnormally large amounts of the truncated mutant proteins
in the fibroblasts of P2 and P5. Relative quantification of the
bands showed that the T761fs (∼89 kD) and I719fs (∼82 kD)
mutant proteins were approximately five and seven times more
abundant than the WT protein in P2 and P5, respectively. Pri-
mary fibroblasts from P6 and P7 were then cultured for 30 min
to 4 h in the presence of cycloheximide (to block de novo protein
synthesis) before flow cytometry to assess GP130 expression
(Fig. S4 A). GP130 cell surface expression was more stable in the
fibroblasts of the patients than in those of the controls, sug-
gesting a slower rate of degradation, consistent with the absence
of the recycling motif in the mutant proteins. We therefore as-
sessed STAT1 and STAT3 phosphorylation in primary fibroblasts
from P2, P5, and P9 after starvation in the absence of serum,
comparing the results obtained with those for controls. IL-6/IL-
6Rα and OSM induced strong STAT1 and STAT3 phosphorylation
in the cells of both controls and patients (Fig. 5 D). LIF induced the
phosphorylation of STAT3 only in both controls and patients. IL-6
stimulation induced STAT3 phosphorylation in the controls, but
not in P2, P5, and P9 (Fig. 5 D and Fig. S4 B). By contrast, IL-11
stimulation induced STAT3 phosphorylation in the controls and
P2, but not in P5 and P9. No STAT1 phosphorylation in response to
IL-11 stimulation was detected in the controls or the patients.
Thus, due to mutant GP130 accumulation at the cell surface,
STAT3 phosphorylation in response to IL-11 stimulation is
strongly impaired in the fibroblasts from P5 and P9, consistent
with the marked skull phenotype of these patients. The normal
response of P2 fibroblasts to IL-11 stimulation is consistent with
the milder skeletal abnormalities observed in kindred A. The
Figure 3. The I719fs and T761fs GP130 mu-
tants are DN over the WT GP130. GP130-
deficient HEK293T cells transfected with a
pCMV6 EV or encoding the WT GP130 (25 ng)
and various concentrations (25–200 ng) of
pCMV6 vector encoding the indicated GP130
mutants (Mut) plus a pGL4.47 reporter plasmid
carrying the luciferase cDNA downstream from
five SIEs. GP130-deficient HEK293T cells trans-
fected with only the WT (25 ng) or the mutant
GP130 (200 ng) were used as controls. Cells were
stimulated, 24 h after transfection, with the indi-
cated cytokine (+) or were left unstimulated (−) for
another 24 h before themeasurement of luciferase
activity. The results shown are the mean and
standard error of the mean for a technical dupli-
cate. Luciferase assays representative of two in-
dependent experiments are shown.
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variability of IL-11 responses observed in vitro in fibroblasts car-
rying slightly different IL6ST mutations remains unexplained.
Subtle differences in functional properties between the mutants
(e.g., the ability to activate the MAPK pathway) may contribute to
these clinical differences. The impairment of these responses
appears to be correlated with the severity of the HIES phenotype
observed in patients bearing DN mutations of IL6ST.
IL6ST mutations underlie typical immunological phenotypes
of HIES
Before investigating the production and function of GP130 in leu-
kocyte subsets, we analyzed the development of these subsets in
patients. The patients’ inflammatory responses were not abolished,
at odds with the IL6ST-AR and IL6R-AR deficiencies (Schwerd
et al., 2017; Spencer et al., 2019), as illustrated by the fever and
increase in C-reactive protein (CRP) levels observed during infec-
tion, at least in P5, P6, and P10 (Fig. 6). Leukocyte counts were
normal in all patients except P3, who had low leukocyte counts.
Within the myeloid compartment, neutrophils and monocytes
were present, and, overall, their numbers were within the normal
range (Table S2). Monocyte subsets and dendritic cell subsets were
present in normal proportions among monocytes and peripheral
blood mononuclear cells (PBMCs), respectively (Fig. 7, A and B).
Eosinophil counts were high in P5, P6, P7, P9, and P10 (Table S2).
Lymphocyte counts were normal in all patients except P2, who
repeatedly had low counts (Table S2). Within the lymphoid com-
partment, B cell counts were normal in all patients except P8, who
had low counts, and P11 and P12, who had elevated counts (Table
S2). The frequency of CD27+ memory B cells was low in all tested
patients (Fig. 7 C). Among memory B cells, the frequencies of IgM+
and IgG+ cells were normal, whereas the frequency of IgA+ was
slightly but significantly lower than normal (Fig. 7 D). Consis-
tent with these findings, serum concentrations of IgG and IgG
subclasses were normal, except in P2 and P6, who had low levels of
total IgG and IgG subclasses (Table S2). Serum IgE concentration
was high in all patients (Table S2). The patients had normal serum
titers of antigen-specific antibodies after infection with common
pathogens, except for P6, who lacked varicella zoster virus–specific
IgG despite a reported history of chickenpox (Table S3). Low-to-
normal levels of IgG againstHaemophilus influenzae, diphtheria, and
tetanus vaccines were detected in all vaccinated patients (Table
S3). Natural killer (NK) cell counts and differentiationwere normal
in all patients, except P6 and P9,who had lowNK cell counts (Fig. 7,
E–G; and Table S2). CD4+ and CD8+ T cell counts were normal
except in P2 and P11, who had lowCD8+ T cell counts and high CD4+
T cell counts, respectively (Table S2). Within the CD4+ and CD8+
T cell compartments, patients had high naive and low central
memory T cell frequencies, respectively (Fig. 7, H and I). The pa-
tients’ CD8+ T cells also contained a low proportion of effector
memory T cells (Fig. 7 I). The proportions of γδ T cells, invariant
natural killer T (iNKT) cells, and regulatory T (T reg) cells were
normal, and the proportion of mucosal-associated invariant T
(MAIT) cells was low (Fig. 7, J and K). Within the memory CD4+
T cell compartment, the frequency of T follicular helper (Tfh) cells
was low, whereas the frequencies of T helper type 1 (Th1), Th17,
and Th1* cells were normal and those of Th2 cells were very high
(Fig. 7 L). This distribution of leukocyte subsets bears some re-
semblance to that of patients with AD-HIES due to STAT3 DN
mutations, who have high frequencies of naive CD4+ T cells, low
frequencies of central memory CD4+ and CD8+ T cells, MAIT cells,
and memory B cells, and high proportions of Th2 cells and low
proportions of Th1* and Th17 cells within the memory CD4+ T cell
compartment (Avery et al., 2010;Minegishi et al., 2007; Chandesris
et al., 2012b; Ma et al., 2012, 2015; Siegel et al., 2011; Wilson et al.,
2015). Overall, the immunological phenotypes of patients with
STAT3 and IL6STmutations are similar, except for the normal Th17
and Th1* frequencies and detectable signs of the acute phase in
patients with IL6ST DN mutations.
IL6ST mutations induce a strong increase in Th2
cytokine production
For confirmation of the results of T helper cell immunophenotyp-
ing, we assessed the capacity of the patients’ memory CD4+ T cells
to secrete Th1, Th2, and Th17 cytokines. We sorted CD4+ memory
T cells from three patients and 12 controls and cultured them for 5 d
with beads coated with monoclonal antibodies against CD3, CD2,
and CD28 and then performed cytokine determinations on the
supernatant. The patients’ memory CD4+ T cells produced normal
levels of IL-2 and Th1 cytokines (TNF and IFN-γ; Fig. 8 A). In
contrast, all three Th2 cytokines examined (IL-4, IL-5, and IL-13)
were strongly increased in culture supernatants of patient memory
CD4+ T cells compared with controls (Fig. 8 B). Th17 cytokine levels
were significantly decreased for IL-17F and IL-22, but not IL-17A
(Fig. 8 C). Moreover, the frequency of IL-17A+, IL-17F+, and IL-22+
memory CD4+ T cells after 5 d of culture with beads coated with
mAbs against CD3, CD2, and CD28 was also significantly decreased
(Fig. 8 D). Finally, we sorted naive CD4+ T cells from DN IL6ST
patients and healthy controls; cultured them with beads coated
with mAbs against CD3, CD2, and CD28 in the presence or absence
of a Th17-polarizing cytokine mixture; andmeasured Th17 cytokine
Figure 4. DN mutants hijack IL-6R. GP130-deficient HEK293T cells trans-
fected with an empty pCMV6 vector or a vector encoding the WT GP130 (25
ng) and a pCMV6 vector encoding the I719fs GP130 mutant (25 ng) plus a
pGL4.47 reporter plasmid carrying the luciferase cDNA downstream from five
SIEs. GP130-deficient HEK293T cells transfected with only the WT (25 ng) or
the mutant GP130 (25 ng) were used as controls. A pCMV6 vector encoding
IL-6R (25 ng) was also used for cotransfection, where indicated. Cells were
stimulated with IL-6 or IL-6 plus IL-6Rα, as indicated, 24 h after transfection
or were left unstimulated for another 24 h before the measurement of lu-
ciferase activity. The results shown are the mean and standard error of the
mean for a technical duplicate. Luciferase assays representative of two in-
dependent experiments are shown.
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secretion after 5 d of stimulation. Patients’ and controls’ naive CD4+
T cells secreted similar levels of IL-17A and IL-17F (Fig. 8 E). Taken
together, these in vitro data reveal an increased Th2 cell response
and a modestly impaired Th17 cell response in DN IL6ST patients
compared with normal controls. The strong Th2 cell response may
account for the high IgE levels and allergies in the patients, whereas
the apparently subnormal Th17 cell response is consistent with the
rarity of CMC, which was observed in only 1 of the 12 patients.
IL6ST expression is up-regulated in the patients’ PBMCs
We used flow cytometry to assess GP130 expression in PBMC
subsets from six patients (P2–P7) and controls in basal con-
ditions (Fig. 9, A–E). We detected no GP130 expression in the
CD56dim and CD56bright NK cells of controls and patients (Fig. 9
A). GP130 expression was also undetectable in naive and
memory B cells from the controls, whereas weak GP130 ex-
pression was detectable in naive and memory B cells from the
patients (Fig. 9 B). GP130 expression was detectable in control
and P8-derived EBV-B cell lines, and, as in primary B cells,
GP130 levels were higher in the patients’ cells than in control
cells (Fig. S5 A). GP130 was expressed strongly in the naive CD4+
and CD8+ T cells, and to a lesser extent in memory CD4+ T cells,
from both controls and patients (Fig. 9, C and D). GP130 levels
were slightly but significantly higher in the CD4+ and CD8+ naive
T cells of patients (P2–P7) than in those of controls (Fig. 9, C and D).
No GP130 expression was detected in the CD8+ memory
Figure 5. GP130 production and activity in the patients’ primary fibroblasts. (A and B) GP130 levels in primary fibroblasts, as evaluated by flow cy-
tometry. (A) Representative traces of GP130 expression in primary fibroblasts from P5 and a healthy control are shown, together with traces for the isotypic
control. (B) The graph shows the MFI of GP130 in five independent controls, and two patients (P2 and P5). The bars and error bars for the patients represent
the mean of a duplicate and the standard deviation, respectively. (C) Total protein was extracted from primary fibroblasts and subjected to immunoblotting
with a mAb against GP130 (amino acids 365–619, clone E8). GAPDH was used as a loading control. Western blots representative of three independent ex-
periments are shown. (D) Primary fibroblasts from P2 and P5 and three healthy controls (Ctl, only one shown) were stimulated (Stim) for 15min with IL-6, IL-6/
IL-6Rα, IL-11, LIF, OSM, and IFN-α or left unstimulated (NS), and the phosphorylation of STAT3 (pY705, top panel) and STAT1 (pY701, bottom panel) was then
evaluated by flow cytometry. FACS plots representative of two independent experiments are shown.
Figure 6. Serum CRP levels suggest normal
acute phase in patients. CRP kinetics of P5, P6,
and P10, and CRP levels in P5, P6, and P10 during
the follow-up period. Arrows indicate infections.
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Figure 7. Leukocyte immunophenotyping. (A) Frequencies of monocyte subsets, as assessed by measuring the expression of CD16 and CD14, for controls
(n = 23; C) and patients (P) with AD IL6ST mutations (n = 6). ns, not significant. (B) Frequencies of cDC2 (Lin−HLA-DR+CD11c+CD1c+CD141−), cDC1 (Lin−HLA-
DR+CD11c+CD1c−CD141+), and plasmacytoid DCs (Lin−HLA-DR+CD11c−CD123+) among the PBMCs of controls (n = 32) and patients with AD IL6ST mutations
(n = 6). (C) Frequency of CD27+ memory cells within the B cell compartment of controls (n = 60) and patients with AD IL6STmutations (n = 6). (D) Frequency of
IgM+, IgA+, and IgG+ cells within the memory B cell compartment of controls (n = 39–60) and patients with AD IL6ST mutations (n = 6). (E–G) NK cell im-
munophenotyping for controls (n = 58–60) and patients with AD IL6ST mutations (n = 6), showing the frequency of CD56bright cells within the NK-cell
compartment (E), the terminal differentiation profile of the CD56dim compartment (F), and the frequency of NKG2C+NKG2A− cells within the CD56dim com-
partment (G). (H and I) Frequency of naive (CD45RA+CCR7+), central memory (CD45RA−CCR7+), effector memory (CD45RA−CCR7−), and TEMRA
(CD45RA+CCR7−) cells among the CD4+ (H) and CD8+ (I) T cells of controls (n = 65) and patients with AD IL6ST mutations (n = 7). (J) Frequency of γδ T cells
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T cells of patients or controls (Fig. 9 C). GP130 levels in control
PBMCs were high in monocytes, and the patients’ monocytes
had GP130 levels approximately three times higher than those
in control monocytes (Fig. 9 E). We assessed the impact of DN
mutations of IL6ST on lymphocyte subsets by assessing STAT1
and STAT3 phosphorylation in CD4+ and CD8+ T cells (P5–P7),
and B cells from patients (P2–P7), in response to simulation
with IL-6, IL-6/IL-6Rα, IL-27, or IFN-α (Fig. 9, F and G; and Fig.
S5, B and C). STAT3 phosphorylation in CD4+ and CD8+ cells in
response to IL-6, IL-6/IL-6Rα, and IL-27 was partially impaired
relative to controls. STAT3 phosphorylation in response to IL-6/
IL-6Rα and IL-27 was detected in control B cells, suggesting that
they express some GP130 despite of its lack of detection by flow
cytometry. STAT3 phosphorylation in response to IL-6/IL-6Rα
or IL-27 was muchweaker in the patients’ B cells than in control
B cells, consistent with the higher levels of GP130 detected only
in the patients’ cells. We also stimulated EBV-B cells from P8
with IL-6 and IL-27. These cells responded poorly to IL-6 but,
unlike primary B cells, their response to IL-27 was normal and
similar to that of controls (Fig. S5 D). We then sorted monocytes
from P5 and assessed STAT1 and STAT3 phosphorylation after
the stimulation of these cells with IL-6, IL-6/IL-6Rα, IL-27, or
IFN-α (Fig. 9 G). STAT3 phosphorylation was almost totally
abolished in the patients’ monocytes in response to IL-6, IL-6/
IL-6Rα, or IL-27. STAT1 phosphorylation in response to IL-27
stimulation was detected in lymphocytes and monocytes and
was similar in controls and patients. No STAT1 phosphorylation
was detected in response to IL-6 and IL-6/IL-6Rα in the lym-
phocytes and monocytes of controls or patients. All subsets
from patients and controls responded to IFN-α, which served as
a positive control. We also observed normal STAT3 phospho-
rylation after stimulation with IL-10 or IL-21 in B cells and
EBV-B cells from the patients; both these cytokines are GP130
independent (Fig. S5, C and D). These data show that GP130
accumulation at the cell surface is cell-type dependent and that
STAT3 phosphorylation in response to stimulation with GP130-
dependent cytokines is impaired in the patients’ lymphocytes
and monocytes. The strong B cell defect observed ex vivo is
consistent with the impaired B cell immunity of the patients
in vivo.
Discussion
We describe here a form of AD-HIES caused by DN IL6ST var-
iants in 12 patients from 8 unrelated kindreds without STAT3
mutations. The patients have a typical clinical presentation of
AD-HIES with pulmonary infections, severe cystic bronchiec-
tasis, eczema, abnormalities of bones and teeth, and high IgE
levels but with apparently normal acute-phase responses. Im-
paired responses to IL-11 (and perhaps LIF) probably account for
most of the skeletal abnormalities, whereas impaired responses
to IL-6 probably account for most of the immunological abnor-
malities. However, unlike patients with AR partial GP130 or
complete IL11RA deficiency, patients with AD GP130 deficiency
do not have craniosynostosis, presumably due to residual re-
sponses to IL-11 via GP130 (Schwerd et al., 2017; Shahin et al.,
2019; Nieminen et al., 2011). Patients with AD-GP130 deficiency
lack the pathognomonic features of SWS (Mikelonis et al., 2014),
reflecting the presence of residual LIF signaling. Similarly, CMC
(P9) and skin abscesses (P6, P8, P10, and P12) were reported in
only a few patients and thus at a frequency lower than that in
HIES patients with STAT3 mutations (Chandesris et al., 2012b).
This observation is consistent with the near-normal counts of
Th17 cells in the patients described here, at odds with the data
for patients with STAT3mutations (Milner et al., 2008; Ma et al.,
2008, 2015, 2016; de Beaucoudrey et al., 2008). Near-normal
Th17 cell levels and a lack of CMC were observed in patients
with biallelic null mutations of IL6R, IL23R, or IL21R (Kotlarz
et al., 2013; Mart́ınez-Barricarte et al., 2018; Spencer et al.,
2019; Ma et al., 2016). This suggests that IL-6R, IL-21R, and IL-
23R are individually, but not collectively, redundant for Th17 cell
differentiation, accounting for CMC in patients with DN STAT3
or AR ZNF341 deficiency, whose cellular responses to IL-6, IL-21,
and IL-23 are all impaired. AR complete GP130 deficiency causes
a SWS-like disorder with perinatal mortality (Monies et al.,
2019; Chen et al., 2020). Otherwise, the AR and AD forms of
partial GP130 deficiency display a considerable overlap, except
for the lack of craniosynostosis and apparently normal acute-
phase response in the AD form. This suggests that the two dif-
ferent modes of inheritance of IL6ST defects affect overlapping
cellular responses to cytokines of the IL-6 family. Other IL6ST
genotypes may underlie various clinical phenotypes, depending
on the nature of the mutation.
The relatively selective effect of mutant GP130 proteins
lacking all four STAT3-binding sites on the different members of
the IL-6 family of cytokines can be explained by the intrinsic
signaling capacity of the coreceptors. IL-6 and IL-11 bind IL-6R
and IL-11R, respectively, with high affinity, and they then recruit
GP130 (Taga et al., 1989; Hibi et al., 1990; Yamasaki et al., 1988;
Hilton et al., 1994; Chérel et al., 1995). By contrast, LIF-R, OSM-R,
and IL-27RA have a low affinity for their respective ligands, and
they require GP130 to form high-affinity receptors (Gearing
et al., 1992; Pflanz et al., 2004). Moreover, IL-6R and IL-11R
chains have short intracellular tails and are therefore strictly
dependent on GP130 for STAT3 activation (Yamasaki et al., 1988;
Hilton et al., 1994). By contrast, LIF-R, OSM-R, and IL-27RA can
activate STATs via their own intracellular tails (Nicola and
Babon, 2015; Hermanns, 2015; Murakami et al., 2019). The pa-
tients’ truncated GP130 mutant proteins can probably form
high-affinity IL-27, LIF, and OSM receptors. The formation of
(CD3+TCR-γδ+), MAIT (CD3+CD161+TCR-vα7.2+), and iNKT (CD3+TCR-iNKT+) cells among the T cells of controls (n = 31–59) and patients with AD IL6ST
mutations (n = 6). (K) Frequency of T reg (CD3+CD4+CD25hiFoxP3+) cells in the CD4+ T cell compartment of controls (n = 59) and patients with AD IL6ST
mutations (n = 7). (L) Frequency of Th subsets within the CD4+ memory compartments of controls (n = 60–64), and patients with AD IL6ST mutations (n = 7).
Subsets were defined as follows: Tfh (CXCR5+), Th1 (CXCR5−CXCR3+CCR4−CCR6−), Th2 (CXCR5−CXCR3−CCR4+CCR6−), Th1* (CXCR5−CXCR3+CCR4−CCR6+),
and Th17 (CXCR5−CXCR3−CCR4+CCR6+). (A–L) t tests were used for all comparisons.
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high-affinity receptors, coupled with the intrinsic signaling ca-
pacity of the coreceptor, probably explains the weak but de-
tectable STAT1 or STAT3 phosphorylation in HEK-GP130-KO
cells transfectedwith the GP130mutants and stimulated with IL-
27, LIF, or OSM (Fig. S1, D and E). Consistently, IL-27–induced
luciferase activity is not completely impaired in HEK-GP130-KO
cells transfected with these mutants (Fig. 2 E and Fig. S2 A). We
also observed weak luciferase activity following the stimulation,
with LIF and OSM, of HEK-GP130-KO cells transfected with the
EV, consistent with the weak affinity of LIF and OSM for LIF-R
and OSM-R and the intrinsic signaling capacity of these two
receptors (Fig. 2 E and Fig. S2 A; Nicola and Babon, 2015;
Hermanns, 2015; Murakami et al., 2019). However, surprisingly,
we did not detect an enhancement of luciferase responses to LIF
or OSM in HEK-GP130-KO cells transfected with a truncated
GP130 mutant from HIES patients relative to cells transfected
with an EV. This suggests that the formation of high-affinity
trimers with a truncated GP130 did not significantly enhance
the signal over that for the low-affinity dimers formed between
LIF or OSM and LIF-R or OSM-R.
The strongest DN effects of the mutant GP130 proteins
against IL-6 and IL-11 signaling are explained in part by the
coreceptors’ lack of intrinsic signaling ability. It can also be
explained by the valence of the multimers formed and/or the
accumulation of DN GP130 mutant proteins at the cell surface.
IL-6, IL-6R, and GP130 or IL-11, IL-11R, and GP130 form hexamers
with a 2:2:2 stoichiometry essential for signal transduction
(Murakami et al., 1993; Barton et al., 2000). By contrast, IL-27,
LIF, and OSM form trimers with GP130 and their coreceptors
(Gearing et al., 1992; Mosley et al., 1996; Pflanz et al., 2004). If
each trimer requires one functional GP130 molecule and each
hexamer requires two suchmolecules to transduce a signal, then
a stronger DN effect would be expected for hexamers (Fig. 10, A
and B). This phenomenon is probably amplified by the greater
accumulation of mutant GP130 proteins in some cell types (e.g.,
HEK293T, monocytes, and fibroblasts) than in others (Fig. 10 C).
For example, at a Mut:WT ratio of 1:1, 50% of trimers but only
25% of hexamers are functional. At a ratio of 4:1, 20% of trimers
but only 4% of hexamers are functional. Consequently, the DN
effect is stronger against IL-6 and IL-11 than against LIF, ac-
counting for the patients having the HIES-AD phenotype rather
than SWS. Intriguingly, however, the mutants lacking all four
STAT3-binding sites have a DN effect on IL-6/IL-6Rα stimula-
tion (trans-signaling) only at a very high Mut:WT ratio (8:1),
whereas they have a strong DN effect on IL-6 stimulation
alone (classic signaling) at a low Mut:WT ratio (e.g., 1:1). Co-
transfection with IL-6R weakened the DN effect of the GP130
mutants in response to IL-6 alone. This suggests that a limited
pool of membrane-anchored coreceptors exacerbate the DN ef-
fect. In other words, a critical activation threshold is less likely
to be reached if the coreceptors are limiting because of compe-
tition for accessibility.
Even though the T761fs mutant has lost all four STAT3-
binding domains and the recycling motif, it is the only HIES-
causing mutant in which the tyrosine 759 (Y759) residue is
retained. Upon phosphorylation, Y759 acts as a docking site for
SOCS3, which switches off STAT3 activation (Nicholson et al.,
2000; Schmitz et al., 2000). The knock-inmouse line expressing
human GP130 with a homozygous Y759F mutation has spleno-
megaly, lymphadenopathy, enhanced acute-phase reactions, and
prolonged STAT3 activation (Ohtani et al., 2000). Moreover,
Y759 acts as a docking site for SHP2, triggering the second
pathway of GP130 activation through MAPK (Fukada et al., 1996;
Figure 8. In vitro functional assays of CD4+ Th cells. (A–C) Secretion (ng/
ml) of IL-2, Th1 (IFN-γ and TNF; A), Th2 (IL-4, IL-5, and IL-13; B), and Th17 (IL-
17A, IL-17F, and IL-22; C) cytokines by memory CD4+ T cells after 5 d of
stimulation with anti-CD2/CD3/CD28 mAb-coated beads. C, control; P, pa-
tients. (D) Frequency of Th17 (IL-17A, IL-17F, and IL-22) cytokine-positive
memory CD4+ T cells after 4 d of culture under Th0 conditions (anti-CD3/
CD2/CD28 antibody-coated beads). (E) Secretion (ng/ml) of Th17 (IL-17A and
IL-17F) cytokines by naive CD4+ T cells after 5 d of culture under Th0 cell–
polarizing conditions (anti-CD2/CD3/CD28 mAb-coated beads) or Th17
cell–polarizing conditions (anti-CD2/CD3/CD28 mAb-coated beads together
with IL-1β, IL-6, IL-21, IL-23, and TGF-β). Mann–Whitney tests were used for
all comparisons. ns, not significant. *, P < 0.05; **, P < 0.01.
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Figure 9. GP130 production and activity in primary lymphocytes and monocytes from patients. (A–E) GP130 levels, as evaluated by flow cytometry, in
primary CD56bright and CD56dim NK cell subsets (A), naive and memory B cells (B), naive and memory CD8+ T cells (C), naive and memory CD4+ T cells (D), and
monocytes (E). The graphs show the MFI of GP130, as measured by flow cytometry, in eight controls (C) and six patients (P2–P7). Representative data for
GP130 expression in naive B cells (B) and monocytes (E) from P2 and a healthy control are shown, together with data for the isotypic control. (A–E) t tests were
used for all comparisons. (F) PBMCs from P6 (red lines) and a control (black lines) were stimulated for 15 min with IL-6, IL-6/IL-6Rα, IL-27, or IFN-α or left
unstimulated, and the phosphorylation of STAT3 (pY705) and STAT1 (pY701) was then evaluated in the indicated subsets. (G) Purified monocytes from P5 (red
lines) and a control (black lines) were stimulated for 15 min with IL-6, IL-6/IL-6Rα, IL-27, or IFN-α or left unstimulated, and the phosphorylation of STAT3
(pY705) and STAT1 (pY701) was then evaluated. ns, not significant.
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Nakajima et al., 1996; Yamanaka et al., 1996). Interestingly, the
ability of GP130mutants lacking all four STAT3 binding sites but
retaining the Y759motif to activate theMAPK pathway has been
tested (Lehmann et al., 2003). These mutants were shown to
retain their ability to activate the MAPK pathway, unlike mu-
tants lacking Y759 and all four STAT3-binding sites. Consistent
with these findings, the T761fs mutant of kindred A, the only
mutant retaining Y759 in our series of HIES kindreds with AD
GP130 deficiency, was able to activate the MAPK pathway. It
may be no coincidence that kindred A had the mildest pheno-
type, with few, if any infections. On a related note, there are 13
predicted heterozygous LOF mutations of this gene in gnomAD,
9 of which are predicted to impair cell surface expression and
not act in a DN manner. The other four predicted heterozygous
LOF mutants lack one, two, or three STAT3-binding domains.
None of these LOF mutants lack all four STAT3 domains, and
none lack the recycling domain. At odds with our initial pre-
diction, at least two of the three mutants tested (S789* and
E899fs) are LOF and DN for cellular responses to IL-6 and IL-11
in vitro. However, the DN effect is milder than that of HIES-
causing mutants, probably because these two mutants retain the
recycling motif and at least one STAT3-binding site. It is
tempting to speculate that these two variants are associatedwith
clinical phenotypes milder than full-blown HIES. Nevertheless,
it will be important to compare the biological and clinical phe-
notypes of patients with AD STAT3, AR ZNF341, and AR and AD
partial GP130 deficiencies carefully, as these deficiencies all
impair at least STAT3-dependent responses to IL-6 and IL-11 and
seem to be clinical phenocopies, but not necessarily strict ones.
Materials and methods
Case reports
P1 (kindred A, Fig. 1 A) was born to nonconsanguineous French/
Greek parents. He is the father of P2 and the grandfather of P3
and P4. He suffered from asthma associated with mild but
Figure 10. IL6ST DNmutation mechanism of action. (A) At a 1:1 Mut:WT ratio, truncated GP130 is predicted to impair 75% of GP130 downstream signaling
hexamers (IL-6/IL-6R/GP130 or IL-11/IL-11RA/GP130) and 50% of GP130 downstream signaling trimers (IL-27/IL-27RA/GP130, LIF/LIF-R/GP130, or OSM/OSM-
R/GP130). (B) The accumulation of mutant GP130 is predicted to have a stronger impact on IL-6 family cytokines forming hexamers (IL-6 and IL-11) than on
those forming trimers (IL-27, LIF, and OSM) with GP130. (C) Mechanism of GP130 accumulation at the cell surface. Due to the missing recycling motif,
truncated GP130 is not recycled in the basal state, unlikeWT GP130. As a result, in heterozygous individuals, truncated GP130 is predicted to accumulate at the
cell surface, whereas WT GP130 is predicted to be stably expressed due to a balance between de novo production and proteosomal degradation.
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recurrent skin infections. No recent biological or clinical data
are available for P1, and it was not therefore possible to calculate
an National Institutes of Health (NIH) HIES score (Grimbacher
et al., 1999b).
P2 (kindred A, Fig. 1 A) was born in 1972 and is the only child
of nonconsanguineous French parents. He is currently 47 yr old.
He is the son of P1 and father of P3 and P4. P2 has had eczema
since early childhood, which improved when he reached adult-
hood. Complete deciduous tooth retention was successfully
treated at the age of ∼20 yr. P2 has mild facial dysmorphism
resembling that of HIES due to heterozygous STAT3 mutations
and scoliosis with a Cobb angle of 11° at the age of 44 yr. He has
hyperextensible ankles and shoulders and has suffered numer-
ous ankle sprains and shoulder dislocations. He has never suf-
fered from bone fractures, and bone densitometry results were
normal. He has never had candidiasis or pulmonary infections
but reported delayed healing of cutaneous injuries, requiring the
use of antibiotics. P2 has no allergies, and has an NIH HIES score
of 27 (Grimbacher et al., 1999b).
P3 and P4 (kindred A, Fig. 1 A) were born in 2003 and 2006
and are currently 16 and 13 yr old, respectively. They are the son
and daughter of P2. P3 was born at 8 mo of pregnancy and had a
neonatal infection requiring intensive care. He had numerous
ear, nose, and bronchial infections during the first 6 yr of life.
Infections stopped after the initiation of prophylactic trimeth-
oprim/sulfamethoxazole. P3 has no facial dysmorphism but
presented a retention of deciduous teeth, which were surgically
removed. He had mild eczema requiring intermittent treatment
with topical steroids. He has never had skin abscesses or can-
didiasis. He has moderate scoliosis and hyperextensibility, re-
sulting in frequent shoulder dislocations. He fractured his right
humerus in a fall from his bike. He had pneumonia at the age of
13 yr, which was caused by H. influenzae and required intrave-
nous antibiotics. Chest computed tomography (CT) showed a
complete resolution of this episode, without the development of
bronchiectasis or pneumatocele. Chest CT also revealed bron-
chomalacia of the left stump bronchus (Fig. 1 B). The NIH HIES
score of P3 was 29. P4 is the sister of P3, and the daughter of P2.
She was born at term and had to be hospitalized at the age of 1 yr
for osteomyelitis of the wrist. She recovered, without paren-
chymal sequelae, from single pneumonia with concomitant
herpes zoster infection in 2015. She displays mild facial dys-
morphism, had to have several deciduous teeth removed surgi-
cally, and has moderate eczema requiring topical treatment. The
NIH HIES score of P4 is 20 (Grimbacher et al., 1999b).
P5 (kindred B, Fig. 1 A) was born in France in 1993 to non-
consanguineous parents and is currently 26 yr old. P5 is of ad-
mixed French and North African descent. He was born at term
without complications. He has suffered from asthma and bron-
chiectasis since the age of 4 yr. He reported Staphylococcus aureus
lung infection at the age of ∼10 yr. In 2010, at the age of 17 yr, he
presented with hemoptysis. Chest CT showed bilateral bron-
chiectasis. Between 2011 and 2017, his respiratory condition
progressively worsened. In 2016, chest CT showed cylindrical
and cystic bronchiectasis in the upper lobes, mainly in the right
upper lobe. In January 2017, he was admitted for a lung abscess
caused by Escherichia coli, resulting in a large persistent
pneumatocele in the right upper lobe (Fig. 1 B). In August 2017,
chronic pulmonary aspergillosis was diagnosed on the basis of
very high anti-Aspergillus precipitin levels, a thickening of the
cavity wall, and the appearance of a fungal ball on chest CT,
which was treated with voriconazole. Imaging also showed a
worsening of cystic bronchiectasis in the left upper and right
lower lobes. HIES was suspected, and immunoglobulin substi-
tution and cotrimoxazole prophylaxis were initiated. In March
2019, P5 was admitted for hemoptysis related to uncontrolled
pulmonary aspergillosis. Liposomal amphotericin B and caspo-
fungin replaced the previous treatment. Susceptibility tests on
the Aspergillus fumigatus strain isolated from the patient revealed
resistance to itraconazole, voriconazole, and isavuconazole due
to a TR34/L98H mutation of cyp51A. Caspofungin and pos-
aconazole replaced the previous treatment. The patient also ex-
periencedmultiple bacterial superinfections of the pneumatocele
after its formation. Pulmonary function tests in June 2019
showed severe obstructive lung disease resulting in a forced
expiratory volume in 1 s of 1.1 liter or 27% the predicted value,
with pronounced hyperinflation. P5 has never suffered from
eczema, skin infections, or CMC. He has suffered from allergic
rhinitis, and skin prick test results were positive for house dust
mite and Alternaria. P5 has no facial dysmorphism but does have
hyperextensible thumbs. A clubfoot was surgically corrected
when the patient was 1 yr old. P5 displayed deciduous tooth re-
tention, requiring the surgical extraction of 24 supernumerary
teeth. From the age of 12 yr, he developed scoliosis, necessitating
orthopedic care (Fig. 1 B). In 2017, he broke two ribs while
coughing. Bone densitometry in 2018 demonstrated osteoporosis.
The NIH HIES score of P5 is 48 (Grimbacher et al., 1999b).
P6 (kindred C, Fig. 1 A) was born in 1980 to second-cousin
parents and is currently 39 yr old. P6 and his wife are of Bul-
garian descent. P6 is the father of P7. He presented with severe
eczema, allergic asthma, recurrent upper and lower respiratory
tract infections, diffuse severe cystic bronchiectasis and recur-
rent bacterial skin abscesses requiring drainage during child-
hood and adolescence. Since 2012, he has suffered from allergic
bronchopulmonary aspergillosis with high levels of Aspergillus-
specific antibodies (IgE and IgG), managed with long-term oral
steroid treatment. Skin prick tests were positive for A. fumigatus
and Alternaria. At the age of 25 yr, P6 presented with massive
hemoptysis related to combined cavitary pulmonary aspergil-
losis and mucormycosis in a large bronchiectasis cavity in the
right upper lobe. Both A. fumigatus and fungi from the order
Mucorales were isolated from respiratory secretions, and the
patient was successfully treatedwith posaconazole for 3 yr. Even
after the cessation of oral corticosteroid treatment, profound
hypogammaglobulinemia persisted, with low levels of the IgG2
and IgG3 subclasses and IgA deficiency. Weekly subcutaneous
immunoglobulin treatment was initiated; the specific pneumo-
coccal antibody response was not assessed. Other pathogens,
such as Pseudomonas aeruginosa, H. influenzae, and S. aureus, are
frequently isolated from the patient’s sputum, leading to fre-
quent exacerbations of his underlying bronchiectasis. In 2019,
the patient was readmitted with hemoptysis related to a relapse
of A. fumigatus superinfection of the largest cavity in the right
upper lobe and an endobronchial fungal ball in the left lung, both
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confirmed by a high galactomannan antigen load and the de-
tection of A. fumigatus in PCR tests on bronchoalveolar lavage
fluid. The severe hemoptysis necessitated bronchial artery em-
bolization and the prompt reinitiation of antifungal treatment
with voriconazole. P6 has frontal bossing and supernumerary
teeth, which were either retained or shed late. He smoked daily
until 8 yr ago. The NIH HIES score of P6 is 47 (Grimbacher et al.,
1999b).
P7 (kindred C, Fig. 1 A) was born in 2007 to non-
consanguineous parents and is currently 12 yr old. P7 is the
daughter of P6. She suffers from atopic eczema, severe allergic
asthma, and recurrent otitis, sinusitis, and bronchitis. She pre-
sented with left upper lobe pneumonia. Chest CT showed
chronic bronchitis without bronchiectasis. She is allergic to
house dust mite, grass, animals, and some foods (cow’s milk and
eggs), without anaphylactic reactions. She presented with re-
current bacterial skin infections without abscesses. Like her
father, she has supernumerary teeth, and she shed her decidu-
ous teeth late. She has no frontal bossing and no facial dys-
morphism but a high palate. Unlike her father, she has normal
serum total IgG and IgG subclass levels and normal antibody
responses to both nonconjugated and conjugated vaccines. The
NIH HIES score of P7 was 37 (Grimbacher et al., 1999b).
P8 (kindred D, Fig. 1 A) was born to nonconsanguineous
parents and is currently 25 yr old. P8 is of Slovak descent. A
clinical case report relating to P8 has been published (Boeck
et al., 2001). Both P8 and his mother suffer from Saethre–
Chotzen syndrome due to a heterozygous deletion in TWIST.
However P8 also presented HIES, and because an immune
phenotype has never been reported in TWIST patients, he was
suspected to have a second genetic defect. Recurrent infections,
severe staphylococcal pneumonia, purulent lymphadenitis, and
conjunctivitis were noted during the patient’s first 18 mo of life.
Repeated staphylococcal abscesses were found, predominantly
in the groin (Fig. 1 B). P8 also had staphylococcal abscesses in the
neck, eventually leading to the removal of multiple lymph nodes
at the age of 5 yr. P8 also suffered from mild eczema on the
chest, face, and hands. His IgE level was regularly >10,000 IU/
ml. The NIH HIES score of P8 was 38 (Grimbacher et al., 1999b).
P9 (kindred E, Fig. 1 A) was born in 1992 to non-
consanguineous parents and was 27 yr old at the time of her
death from overwhelming pulmonary infection. She was half
Mexican and half Salvadoran. She suffered from recurrent in-
fections, including onychomycosis, five episodes of shingles
between the ages of 2 and 20 yr, and recurrent otitis, pharyn-
gitis, sinusitis, and bronchopulmonary infections. She reported
12 episodes of lung infection before the age of 13 yr and fre-
quently required antibiotics thereafter. At the age of 13 yr, she
suffered pneumonia complicated by empyema requiring chest
drainage. From the age of 24 yr, she was hospitalized onmultiple
occasions for recurrent (despite partial pneumonectomy) right
multifocal pneumonia resulting in multiple cystic and cavitary
lesions (Fig. 1 B). She underwent endoscopic sinus surgery
(Fig. 1 B), leading to an improvement in nasal symptoms, and
culture demonstrated Aspergillus infection. Additional infections
included pyelonephritis, with E. coli growing in cultures, at the
age of 20 yr, and right foot cellulitis progressing to abscess and
requiring incision, drainage, and intravenous antibiotics at the
age of 22 yr. At the age of 23 yr, the patient suffered a left ankle
fracture after twisting her ankle while walking in heels. The
fracture required surgery, which was then complicated by S.
aureus infection requiring incision, drainage, and intravenous
antibiotics. The patient had a high palate, deciduous tooth re-
tention, joint hyperextensibility, and scoliosis. She did not have
craniosynostosis. She suffered from asthma and was treated
with oral steroids on multiple occasions annually. She suffered
from eczema and allergic rhinitis. The NIH HIES score of P9 was
66 (Grimbacher et al., 1999b).
P10 (kindred F, Fig. 1 A) was born in 1992 to non-
consanguineous Turkish parents. A clinical case report relating
to P10 has been published (Saçilanateş et al., 2005). P10 suffered
from pustular skin lesions from the age of 1 wk, with umbilical
cord separation at 16 d. She had severe atopic dermatitis and
recurrent sinopulmonary infections from the age of 6 mo. She
had S. aureus pneumonia complicated by empyema requiring a
chest tube at the age of 8 yr. She had several episodes of
pneumonia between the ages of 8 and 10 yr, and pneumatocele
was detected on chest CT. At the age of 10 yr, numerous cavities
were detected, and she consulted for thoracic surgery for
pneumatocele excision, the largest cavity being located in the
left upper lobe. This patient had no facial dysmorphism or sco-
liosis. Her deciduous teeth fell out spontaneously, but late.
She fractured her left humerus twice in falls. Physical exami-
nation revealed eczema, scars of old pustular lesions, hyper-
extensibility, and clubbing. P10 had eosinophilia and a total IgE
level of 13,778 IU/ml. AD-HIES was suspected, so cotrimoxazole
prophylaxis and immunoglobulin replacement therapy were
initiated. At the age of 15 yr, P10 underwent surgery for a sep-
tated pneumatocele with a diameter of 8 × 5 × 8 cm in the left
upper lobe. Pathology results were consistent with chronic fi-
brinous pleurisy with Aspergillus colonization. P10 was lost to
follow up between 2007 and 2014 but received regular intra-
venous Ig (IVIg) treatment and cotrimoxazole prophylaxis. She
was admitted to the local hospital for hemoptysis in 2012, and
bleeding in the right bronchial and right intercostal arteries was
controlled by embolization. In January 2014, at the age of 22 yr,
she was admitted for hemoptysis of 2 mo duration. Chest CT
showed a severe worsening of the condition of the lung paren-
chyma (Fig. 1 B), with images consistent with bleeding in the
right lung, upper lobe anterior cyst, and bronchus dilation.
Thoracic aortography and bronchial arteriography were per-
formed, and active hemorrhagingwas detected in both bronchial
arteries. Embolization was performed on all bleeding arteries.
P10 was intubated and evaluated for lung transplantation. Her
clinical condition deteriorated within 2 wk, and extracorporeal
membrane oxygenation support was provided. She died be-
fore lung transplantation. The NIH HIES score of P10 was 52
(Grimbacher et al., 1999b).
P11 (kindred G, Fig. 1 A) was born in 2001 to non-
consanguineous American parents and is currently 18 yr old. P11
is of European descent. He has had allergic rhinitis and mild
asthma since early childhood, controlled with inhaled flutica-
sone and, when required, albuterol. At the age of 9 yr, he pre-
sented with a cough of a few months’ duration and acute fever.
Béziat et al. Journal of Experimental Medicine 17 of 24








ent user on 08 M
ay 2020
Chest imaging revealed a large cavitary lesion, bronchiectasis,
and patches of infiltrate, and bronchoalveolar lavage was posi-
tive for A. fumigatus. Antifungal drugs were therefore initiated.
Approximately 4 mo after initial presentation, he developed
spontaneous pneumothorax complicated by a persistent bron-
chopleural fistula. Allergic bronchopulmonary aspergillosis was
diagnosed, and the patient was treated with intermittent corti-
costeroids for flare-ups and was included in an omalizumab
trial. The patient also has a history of esophagitis, primary tooth
retention requiring the extraction of eight teeth, wrist fracture,
and arthralgia. P11 has no full siblings, but two half siblings and
the parents of this patient are healthy. He has two half siblings
who are healthy. Serum IgG, IgA, and IgM levels have remained
within normal limits, and specific antibodies against tetanus and
pneumococcal were present. Serum IgE concentrations for this
patient range from 250 to 13,000 IU/ml. The NIH HIES score of
P11 is 52 (Grimbacher et al., 1999b).
P12 (kindred H, Fig. 1 A) was born in 1998 to noncon-
sanguineous American parents and is currently 22 yr old. P12 is
of European descent. Hewas diagnosedwith asthma at the age of
2 yr and had recurrent asthma exacerbations as a child. He had
symptoms of mild nasal allergies but no eczema. Thirteen of his
deciduous teeth were retained, and the patient displayed mild
scoliosis that did not require treatment. He had recurrent and
recalcitrant tinea pedis and one skin abscess. He received all
routine childhood vaccines, including live vaccines, without
adverse events. At the age of 12 yr, he had osteomyelitis of the
elbow. The same year, he underwent bronchoscopy for recur-
rent pneumonia; Aspergillus was grown from the bronchoscopy
specimen, leading to the patient being placed on prednisone and
itraconazole. At the age of 17 yr, after multiple hospitalizations
and chest tube placements, he was found to have bronchiectasis
with invasive aspergillosis of the lungs and fungal invasion of
the arteries and underwent right middle lobe and lower lobe
resection. Treatment with itraconazole continued until the
hospitalization of this patient in 2019 for hemoptysis and severe
pneumonia (bronchoalveolar lavage showing Aspergillus and
methicillin-sensitive S. aureus), with a chest CT scan showing
finger-in-glove mucoid impaction and bronchiectasis. He is
currently relatively stable as an outpatient for 6 mo, having
completed his course of prednisone, on bactrim, voriconazole,
and subcutaneous immunoglobulins. His IgE levels were high,
and he was initially diagnosed with common variable immu-
nodeficiency at the age of 18 yr (low IgG levels and a lack of
specific antibody response). This patient did not develop pneu-
monia during 3 yr of IVIg treatment, but IVIg was stopped when
he reached the age of 21 yr due to a lack of health insurance
coverage. This patient’s family history includes a father with
severe, steroid-dependent asthma, rheumatoid arthritis, multi-
ple infections, and diverticulitis requiring colostomy, who died
at the age of 26 yr after prolonged hospitalization in an intensive
care unit. The NIH HIES score of P12 is 44 (Grimbacher et al.,
1999b).
The experiments described here were conducted in accor-
dance with local, national, and international regulations and
were approved by the French Ethics committee, French National
Agency forMedicines and Health Product Safety, and the French
Ministry of Research. Informed consent was obtained from all
patients or their families, in the case of minors, in accordance
with the World Medical Association, the Helsinki Declaration,
and European Union directives.
WES
WES was performed with individual institutional protocols. We
extracted genomic DNA from blood samples collected from the
patients and their parents and siblings with the iPrep PureLink
gDNA Blood Kit and iPrep Instruments from Life Technologies.
WES was performed for all patients except P1 and P7. Exome
capture was performed with the SureSelect Human All Exon
71 Mb kit (Agilent Technologies). Paired-end sequencing was
performed on a HiSeq 2500 machine (Illumina) generating 100-
base reads. We aligned the sequences with the GRCh37 reference
build of the human genome using the Burrows-Wheeler Aligner
(Li and Durbin, 2010). Downstream processing and variant
calling were performed with the Genome Analysis Toolkit
(McKenna et al., 2010), SAMtools (Li et al., 2009), and Picard
tools. Substitution and InDel calls were made with the GATK
UnifiedGenotyper. All variants were annotated with annotation
software developed in-house (Adzhubei et al., 2010; Kircher
et al., 2014; Ng and Henikoff, 2001).
Sanger sequencing
Genomic DNA was obtained from whole blood from patients.
The IL6ST mutation was amplified from genomic DNA by PCR;
the PCR products were purified by centrifugation through Se-
phadex G-50 Superfine resin (Amersham-Pharmacia-Biotech)
and sequenced with the BigDye Terminator Cycle Sequencing
Kit (Applied Biosystems). Sequencing products were purified by
centrifugation through Sephadex G-50 Superfine resin, and se-
quences were analyzed with an ABI Prism 3500 apparatus
(Applied Biosystems). The sequences obtained were aligned
with the genomic sequence of IL6ST (Ensembl) with Serial
Cloner 2.6 software.
Cell culture
PBMCs were isolated by Ficoll-Hypaque centrifugation (Amer-
sham-Pharmacia-Biotech) from cytopheresis or whole-blood
samples obtained from healthy volunteers and patients, re-
spectively. Primary human fibroblasts were isolated from a
5-mm skin punch biopsy or from surgical skin margins from
healthy donors. Briefly, epidermiswas separated from dermis by
dispase (BD Bioscience) digestion overnight at +4°C, and the
keratinocytes were isolated from the epidermis by scraping into
a trypsin solution (Thermo Fisher Scientific). The dermis was
cut into pieces and the explants were kept in DMEM supple-
mented with 10% fetal bovine serum (Sigma-Aldrich) for 10–15 d
for fibroblast isolation. Primary fibroblasts and HEK293T cells
were cultured in DMEM supplemented with 10% fetal bovine
serum. EBV-B cell lines were maintained in RPMI 1640 supple-
mented with 10% fetal bovine serum (Sigma-Aldrich).
Generation of GP130-deficient HEK293T cells
GP130-deficient HEK293T cells were generated with the
CRISPR/Cas9 system. Guide RNAs were designed with the
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Benchling design tool, and inserted into lentiCRISPR v2, which
was a gift from Feng Zhang (plasmid #52961; Addgene). The
guide RNAs (forward: 59-CACCGTATGTACTTACTATCTTCAT-
39; reverse: 59-AAACATGAAGATAGTAAGTACATAC-39) were
designed to bind to intron 8 and to cut in exon 8. Using
X-tremeGENE 9 DNA Transfection Reagent (Roche), we tran-
siently transfected WT HEK293T cells with the resulting plas-
mid and cultured them for 5 d in the presence of puromycin
before sorting the GP130− cells. The resulting cell line was
subsequently tested for impaired GP130 expression and func-
tion and normal STAT1 and STAT3 expression.
Plasmids and transient transfection
The C-terminal Myc/DDK-tagged pCMV6 EV, the human IL6ST,
and IL6R expression vectors were purchased from Origene.
Constructs carrying mutant alleles were generated by direct
mutagenesis with the QuikChange II XL Site-Directed Muta-
genesis Kit (Agilent Technologies), according to the manu-
facturer’s instructions. A stop codon was introduced by
mutagenesis between the IL6ST cDNA and the Myc/DDK tag.
HEK293T cells were transiently transfected with the various
constructs, with X-tremeGENE 9 DNA Transfection Reagent
(Roche), used according to the manufacturer’s instructions.
Cell lysis, PNGase F treatment, and immunoblotting
For overexpression experiments, GP130-deficient HEK293T cells
were cotransfected with a WT or mutant pCMV6-GP130 vector
or an empty pCMV6 vector and cultured for 24 h before har-
vesting and cell lysis. Total protein extracts were prepared by
mixing cells with lysis buffer (50mMTris, pH 7.4, 150mMNaCl,
2 mM EDTA, and 0.5% Triton X-100) and incubating for 30 min
at 4°C. The cells were centrifuged for 10 min at 16,000 ×g, and
the supernatant was collected for immunoblotting. A mixture of
protease and phosphatase inhibitors was added to the buffers
immediately before use: aprotinin (10 µg/ml; Sigma-Aldrich),
PMSF (1 mM; Sigma-Aldrich), leupeptin (10 µg/ml; Sigma-
Aldrich), protease inhibitor cocktail (1×; Sigma-Aldrich). DNA
was digested with Pierce Universal Nuclease for Cell Lysis
(1/100; Thermo Fisher Scientific) during the lysis step. When
indicated, PNGase F treatment was used in accordance with the
manufacturer’s instructions (New England Biolabs) to eliminate
N-glycosylation. The proteins were separated by SDS-PAGE and
immunoblotting was performed with antibodies against GP130
(E-8; Santa Cruz) and GAPDH (FL335; Santa Cruz).
Immunophenotyping
Immunophenotyping was performed by flow cytometry, with
mAbs against CCR7 (G043H7; Sony), CD1c (L161; BioLegend), CD3
(7D6; Invitrogen; UCHT1; BD), CD4 (RPA-T4; BD), CD8 (RPA-T8;
BD), CD11c (S-HCL-13; BD), CD14 (M5E2; BD), CD16 (3G8; BD),
CD19 (4G7, BD), CD20 (LT20; Miltenyi Biotec), CD25 (MA-251;
BD), CD27 (O323; Sony; L128; BD), CD45RA (Hl100; BD), CD56
(B159; BD; NCAM16.2; BD), CD123 (6H6; BioLegend), CD130/
GP130 (AM64; BD), CD141 (1A4; BD), CD161 (DX12; BD), CD183
(G025H7; BioLegend), CD185/CXCR5 (REA103; Miltenyi Biotec),
CD194/CCR4 (REA279; Miltenyi Biotec), CD196/CCR6 (REA190;
Miltenyi Biotec) FOXP3 (259D/C7; BD), IgA (IS11-8E10; Miltenyi
Biotec), IgG (G18-145; BD), IgM (PJ2-22H3; Miltenyi Biotec),
KIR2DL1/S1 (EB6; Beckman Coulter) KIR2DL2/S2/L3 (GL183,
Beckman Coulter), KIR3DL1 (DX9; BioLegend), NKG2A (REA110;
Miltenyi Biotec), NKG2C (REA205; Miltenyi Biotec), TCR-iNKT
(6B11; BD), TCR-γδ (11F2; Miltenyi Biotec), and TCR-Vα7.2
(REA179; Miltenyi Biotec). We assessed the expression of mutant
and WT GP130 alleles in an overexpression system by trans-
fecting a GP130-deficient HEK293T cell with an empty pCMV6
vector, or WT or mutant pCMV6-GP130, culturing for 48 h, and
then detaching the cells by pipetting for extracellular GP130
staining. For the evaluation of GP130 expression in primary fi-
broblasts, adherent cells were washed in 1 × PBS and detached
with trypsin for GP130 staining. Cells were also stained with the
Aqua Live/Dead Cell Stain Kit (Thermo Fisher Scientific). Where
indicated, primary fibroblasts were incubated with cyclohexi-
mide (10 µg/ml; Sigma-Aldrich) for the indicated time before
staining for extracellular GP130 and with a dead cell marker.
When required, for intracellular staining, cells were fixed and
permeabilized with a fixation/permeabilization kit (eBioscience
or BD) after extracellular staining. Samples were analyzed with
a Fortessa X20 (BD), or Gallios (Beckman Coulter) flow cytom-
eter, depending on the experiment. Data were then analyzed
with FlowJo 10.5.3 software. The terminal differentiation profile
of the CD56dim compartment was investigated by determin-
ing the distribution of NKG2A and KIR (Béziat et al., 2010;
Björkström et al., 2010). P9 immunophenotyping was performed
as previously described (Shahin et al., 2019).
Cytokines
IL-6, IL-11, LIF, and OSMwere purchased fromMiltenyi Biotech.
The IL-6–IL-6Rα fusion protein and IL-27 were purchased from
R&D Systems. IFN-α (Intron A) was purchased from Merck. IL-
6, IL-6–IL-6Rα, IL-11, IL-27, LIF, and OSM were all used at a final
concentration of 100 ng/ml. IFN-α was used at a final concen-
tration of 105 U/ml.
Luciferase reporter assay
Reporter assays were performed as previously described (Béziat
et al., 2018). GP130-deficient HEK293T cells were plated for 24 h
before transfection in DMEM supplemented with 10% FCS. We
assessed the impact of the mutation on GP130 function by
transfecting cells with the pGL4.47{luc2P/SIE/Hygro} (Prom-
ega) reporter plasmids (100 ng/well for a 96-well plate), the
pRL-SV40 vector (40 ng/well), and a WT or mutant pCMV6-
GP130 (100 ng/well) in the presence of X-tremeGENE 9 DNA
Transfection Reagent (Roche). We assessed the DN effect of each
mutant allele by transfecting GP130-deficient HEK293T cells
with the pGL4.47{luc2P/SIE/Hygro} (Promega) reporter plas-
mids (100 ng/well for a 96-well plate), the pRL-SV40 vector
(40 ng/well), the WT pCMV6-GP130 (25 ng/well), and various
concentrations of mutant pCMV6-GP130 (12.5 ng/well, 25 ng/
well, 50 ng/well, 100 ng/well, or 200 ng/well) in the presence of
X-tremeGENE 9 DNA Transfection Reagent (Roche). In the DN
assays, wells transfected with the pGL4.47{luc2P/SIE/Hygro}
(Promega) reporter plasmids (100 ng/well for a 96-well plate),
the pRL-SV40 vector (40 ng/well), and the WT pCMV6-GP130
only (25 ng/well) or the indicated mutant pCMV6-GP130 only
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(200 ng/well) or the empty pCMV6 only (200 ng/well) were also
included as controls. The DNA content of each well was made up
to 365 ng/well with empty pCMV6 vector to ensure that each
well contained the same amount of DNA. For IL-6R cotrans-
fection luciferase experiments, we used 25 ng of the WT
pCMV6-IL6R and 25 ng of the WT and I719fs pCMV6-IL6ST
plasmids in the indicated wells. The DNA content of each well
was made up to 215 ng/well with empty pCMV6 vector to ensure
that each well contained the same amount of DNA. The medium
was removed 24 h after transfection and replaced with DMEM
supplemented with 10% FCS and the indicated cytokines. Ex-
periments were performed with technical duplicates and the
promoter activity of each well is expressed as firefly luciferase
activity/Renilla luciferase activity.
CD4+ T cell isolation and functional characterization
PBMCs were incubated with mAbs against CD4, CD45RA, CCR7,
CD127, and CD25. Naive and memory CD4+ T cells were isolated
by first excluding T reg cells (CD25hiCD127lo) and then sorting
CD4+CD45RA+CCR7+ or CD4+CD45RA−CXCR5−CCR7+/− cells, re-
spectively. Isolated naive and memory CD4+ T cells were then
cultured in 96-well round-bottomed (30–40 × 103 cells/well)
with T cell activation and expansion beads (coated with mAbs
against CD2/CD3/CD28; Miltenyi Biotech) alone (Th0) or under
Th17 cell–polarizing conditions. After 5 d, supernatants were
harvested and the production of IL-4, IL-5, IL-9, IL-10, IL-13, IL-
17A, IL-17F, and IFN-γ was determined by cytometric bead ar-
rays (Becton Dickinson); IL-22 secretion was measured by ELISA
(eBioscience). For cytokine expression, activated CD4+ T cells
were restimulated with PMA (100 ng/ml)/ionomycin (750 ng/
ml) for 6 h, with brefeldin A (10 µg/ml) added after 2 h. Cells
were then fixed, and the intracellular levels of IL-4, IL-9, IL-13,
IL-10, IL-17A, IL-17F, IL-22, IL-21, and IFN-γ were determined.
Phospho-STAT (p-STAT) and ERK experiments
Primary fibroblasts were cultured in DMEM-2% FCS for 16 h and
then in DMEM-0% FCS for 2 h before the assays. For p-STAT
experiments, GP130-deficient HEK293T cells were cultured in
DMEM-10% FCS for 16 h before transfection with the WT or
mutant pCMV6-GP130 or empty pCMV6, and were then cul-
tured for a further 24 h before the assay. For p-ERK1/2 experi-
ments, GP130-deficient HEK293T cells were cultured in DMEM-
10% FCS for 16 h before transfection with the WT or mutant
pCMV6-GP130 or empty pCMV6, were then cultured for 24 h in
DMEM-10% FCS, and starved of serum in DMEM-0.5% FCS for a
further 16 h before the assay. Monocyte experiments were
performed with cells purified from fresh PBMCs (CD14 Mi-
croBeads, Miltenyi Biotec), which were allowed to rest for 2 h at
37°C in RPMI-2% FCS before the assay. Experiments with B cells
and CD4+ and CD8+ T cells were performed with freshly isolated
PBMCs rested overnight in X-VIVO 20 serum-free medium
(Lonza). Levels of p-STAT3 in EBV-B cells were determined in
serum-starved cells, which were then stimulated with IL-6
(50 ng/ml), IL-27 (40 ng/ml), and IL-21 (50 ng/ml) before fixa-
tion. Except for primary fibroblasts and GP130-deficient
HEK293T cells, cells were stained with Aqua Dead cell marker
(Thermo Fisher Scientific) or Fixable Viability Dye eFluor 780
(eBioscience) before incubation with the indicated cytokines for
15 min in the corresponding medium, fixation in Fix buffer I (1:
1 volume; BD Biosciences), and incubation for 10 min at 37°C.
Primary fibroblasts and GP130-deficient HEK293T cells were
incubated with the indicated cytokines for 15 min. The medium
was then removed and the fibroblasts werewashed oncewith 1 ×
PBS to remove dead cells. Adherent fibroblasts and GP130-
deficient HEK293T cells were recovered by treatment with
trypsin andwerewashed once in coldmediumbefore fixation by
incubation for 10 min with Fix buffer I. When required for the
analysis of lymphocyte subsets, cells were stained for extracel-
lular epitopes, including CD4 (RPA-T4, BD), CD8 (BW135/80,
Miltenyi Biotech), and CD3 (Bw264/56; Miltenyi Biotech) before
permeabilization. Cells were then permeabilized by incubation
for 20 min at room temperature in Perm buffer III (BD Bio-
sciences) and stained for 3 h at 4°C with anti-STAT3-pY705 (4/
P-STAT3; BD), anti-STAT1-pY701 (14/P-STAT1), anti-ERK1/2-
pT202/pY204 (20A), or isotypic control antibody. When re-
quired for the analysis of primary B cells, CD20 (H1; BD) was
added together with anti-p-STAT antibodies. Cells were ana-
lyzed on a FACS Gallios machine.
Statistics
Two-tailed Mann–Whitney tests were used for single compar-
isons of independent groups. In the relevant figures, ****, P <
0.0001; ***, P < 0.001; **, P < 0.01; and *, P < 0.05. Analyses were
performed with GraphPad software.
Online supplemental material
Fig. S1 shows expression of the GP130 mutants and phospho-
rylation assays of STAT1 and STAT3. Fig. S2 shows molecular
characterization of the GP130 mutants. Fig. S3 shows an assay of
the negative dominance of the GP130 mutants. Fig. S4 shows
primary fibroblasts. Fig. S5 shows GP130 expression and func-
tion in PBMCs. Table S1 is a clinical summary of IL6ST-DN pa-
tients. Table S2 lists the biological parameters of patients with
DN IL6ST mutations. Table S3 lists the biological parameters of
patients with DN IL6ST mutations. Data S1 lists members of the
Undiagnosed Diseases Network.
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Béziat, V., J. Li, J.-X. Lin, C.S. Ma, P. Li, A. Bousfiha, I. Pellier, S. Zoghi, S.
Baris, S. Keles, et al. 2018. A recessive form of hyper-IgE syndrome by
disruption of ZNF341-dependent STAT3 transcription and activity. Sci.
Immunol. 3:eaat4956. https://doi.org/10.1126/sciimmunol.aat4956
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danèche, S. Dupuis, R. Döffinger, F. Altare, J. Girdlestone, J.-F. Emile,
et al. 1999. A human IFNGR1 small deletion hotspot associated with
dominant susceptibility to mycobacterial infection. Nat. Genet. 21:
370–378. https://doi.org/10.1038/7701
Kane, A., E.K. Deenick, C.S. Ma, M.C. Cook, G. Uzel, and S.G. Tangye. 2014.
STAT3 is a central regulator of lymphocyte differentiation and function.
Curr. Opin. Immunol. 28:49–57. https://doi.org/10.1016/j.coi.2014.01.015
Kawasaki, K., Y.-H. Gao, S. Yokose, Y. Kaji, T. Nakamura, T. Suda, K. Yoshida,
T. Taga, T. Kishimoto, H. Kataoka, et al. 1997. Osteoclasts are present in
gp130-deficient mice. Endocrinology. 138:4959–4965. https://doi.org/10
.1210/endo.138.11.5534
Khourieh, J., G. Rao, T. Habib, D.T. Avery, A. Lefèvre-Utile, M.-O. Chandesris,
A. Belkadi, M. Chrabieh, H. Alwaseem, V. Grandin, et al. 2019. A deep
intronic splice mutation of STAT3 underlies hyper IgE syndrome by
negative dominance. Proc. Natl. Acad. Sci. USA. 116:16463–16472. https://
doi.org/10.1073/pnas.1901409116
Kim, H., T.S. Hawley, R.G. Hawley, and H. Baumann. 1998. Protein tyrosine
phosphatase 2 (SHP-2)moderates signaling by gp130 but is not required
for the induction of acute-phase plasma protein genes in hepatic cells.
Mol. Cell. Biol. 18:1525–1533. https://doi.org/10.1128/MCB.18.3.1525
Kircher, M., D.M. Witten, P. Jain, B.J. O’Roak, G.M. Cooper, and J. Shendure.
2014. A general framework for estimating the relative pathogenicity of
human genetic variants. Nat. Genet. 46:310–315. https://doi.org/10
.1038/ng.2892
Kotlarz, D., R. Beier, D. Murugan, J. Diestelhorst, O. Jensen, K. Boztug, D.
Pfeifer, H. Kreipe, E.-D. Pfister, U. Baumann, et al. 2012. Loss of
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Béziat et al. Journal of Experimental Medicine 24 of 24








ent user on 08 M
ay 2020
Supplemental material
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Figure S1. Expression of the GP130mutants and phosphorylation assays of STAT1 and STAT3. (A) GP130-deficient HEK293T cells were transfected with
an empty pCMV6 plasmid (EV) or with pCMV6 plasmids encoding the WT, L708*, C733*, S742fs, S754*, or Y759* GP130 mutants. Total protein was extracted
and subjected to immunoblotting with a mAb against GP130 (amino acids 365–619, clone E8). GAPDH was used as a loading control. Western blots repre-
sentative of three independent experiments are shown. (B and C) GP130-deficient HEK293T cells were transfected as described in A. After 48 h, the cells were
harvested, stained for extracellular GP130, and analyzed by flow cytometry. Representative staining (B) and a recapitulative graph of GP130 mean fluorescence
intensity (C) are shown. The bars and error bars represent the mean of three independent experiments and the standard deviation, respectively. (D and E)
GP130-deficient HEK293T cells were transfected with an empty pCMV6 plasmid (EV) or with pCMV6 plasmids encoding the WT, or E316*, T555fs, L708*,
I719fs, C733*, S742fs, S754*, Y759*, T761fs, S789*, E899*, G913fs GP130 mutants. After 24 h of incubation, the cells were stimulated for 15 min with the
indicated GP130-dependent cytokines (red line) or left unstimulated (black line), and the phosphorylation of STAT3 (pY705; D) and STAT1 (pY701; E) was then
evaluated by flow cytometry. The results obtained with the I719fs and T761fs mutants are representative of the results obtained with the other mutants found
in HIES patients (L708*, C733*, S742fs, S754*, and Y759*). Representative results from three independent experiments are shown.
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Figure S2. Molecular characterization of the GP130 mutants. (A) STAT3 activity, as assessed in a luciferase assay. GP130-deficient HEK293T cells
transfected with an empty pCMV6 vector (EV) or with a plasmid encoding the WT or the indicated GP130 mutant plus a pGL4.47 reporter plasmid carrying the
luciferase cDNA downstream from five SIEs. Cells were stimulated with the indicated cytokine (+), 24 h after transfection, or were left unstimulated (−) for
another 24 h before the measurement of luciferase activity. The horizontal dotted line indicates the luciferase activity after the stimulation, with the indicated
cytokine, of cells transfected with the empty pCMV6 vector. The results shown are the mean and standard error of the mean for a technical duplicate. A
luciferase assay representative of two independent experiments is shown. (B) STAT3 activity, as assessed in a luciferase assay, after IFN-α stimulation. GP130-
deficient HEK293T cells were transfected as described in A. Cells were stimulated with IFN-α (+), 24 h after transfection, or were left unstimulated (−) for
another 24 h before the measurement of luciferase activity. The horizontal dotted line indicates the luciferase activity after the stimulation, with the indicated
cytokine, of cells transfected with the empty pCMV6 vector. The results shown are the mean and standard error of the mean for a technical duplicate. A
luciferase assay representative of two or three independent experiments is shown. (C) GP130-deficient HEK293T cells were transfected with an empty pCMV6
plasmid (EV) or with pCMV6 plasmids encoding the WT or I719fs, S754*, and T761fs GP130 mutants. After 24 h of incubation, the cells were starved of serum
for 16 h and then stimulated for 15 min with the indicated GP130-dependent cytokines or left unstimulated, and the phosphorylation of ERK1/2 (pT202/pY204;
top panel) or STAT3 (Y705, positive control; lower panel) was evaluated by flow cytometry. Representative results from two independent experiments
are shown.
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Figure S3. Assay of the negative dominance of the GP130 mutants. (A–G) GP130-deficient HEK293T cells transfected with an empty pCMV6 vector or a
vector encoding the WT GP130 (25 ng) and various amounts (25–200 ng) of pCMV6 vector encoding the indicated GP130 mutant (Mut) plus a pGL4.47 reporter
plasmid carrying the luciferase cDNA downstream of five SIEs. GP130-deficient HEK293T cells transfected with only the WT (25 ng) or the mutant GP130 (200
ng) were used as controls. Cells were stimulated with the indicated cytokine 24 h after transfection or were left unstimulated for another 24 h before the
measurement of luciferase activity. The results shown are the mean and standard error of the mean for a technical duplicate. Luciferase assays representative
of two independent experiments are shown.
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Figure S4. Primary fibroblasts. (A) Kinetics of GP130 degradation. Primary fibroblasts from P6, P7, and one healthy control were incubated for the times
indicated (30 min to 4 h) with cycloheximide (CHX) to inhibit protein synthesis. GP130 levels were then evaluated by flow cytometry. The expression levels
shown are normalized relative to the nonstimulated time point (100%). The means and standard errors of the means from three independent experiments are
shown. (B) p-STAT3 in P9. Primary fibroblasts from P9 and one healthy control (Ctl) were stimulated (Stim) for 15 min with IL-6, IL-11, LIF, OSM, and IFN-α or
left unstimulated (NS), and the phosphorylation of STAT3 (pY705) was then evaluated by flow cytometry.
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Figure S5. GP130 expression and function in PBMCs. (A) GP130 levels in EBV-B cell lines from two controls (C1 and C2) and P8. Representative data are
shown on the left and are summarized in a graph on the right. (B) PBMCs from P5 (red lines, left plots), P6 (red lines, right plots), and two controls (black lines)
were stimulated for 15 min with IL-6, IL-6/IL-6Rα, IL-27, or IFN-α or left unstimulated, and the phosphorylation of STAT3 (pY705) was then evaluated in the
indicated subsets. (C) PBMCs of P2-P4 (red lines) and controls (black lines) were stimulated for 15 min with IL-6, IL-6/IL-6Rα, IL-27, IFN-α, IL-10, or IL-21 or left
unstimulated, and the phosphorylation of STAT3 (pY705) was then evaluated in B cells. (D) EBV-B cell lines from P8 and a control were stimulated for 15 min
with IL-6, IL-27, or IL-21 or left unstimulated, and the phosphorylation of STAT3 (pY705) was then evaluated.
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Table S1 is a clinical summary of IL6ST-DN patients. Table S2 lists the biological parameters of patients with DN IL6ST mutations.
Table S3 lists the biological parameters of patients with DN IL6ST mutations. Data S1 lists members of the Undiagnosed
Diseases Network.
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